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ABSTRACT 
This dissertation addresses the interface of genetics, genomics, and older adults 
through a collection of three manuscripts that examine genetic and genomic testing and 
decision-making across age groups. The dissertation offers evaluations of a new lens for 
decision-making in genetics and genomics, a contextualization of the differences and 
similarities of perceptions and beliefs that exist among age groups engaging in direct-to-
consumer personal genetic testing (DTC PGT), an identification of two factors that 
influence the decision to engage in DTC PGT, and an expansion of the current 
applications of Protection Motivation Theory to include disclosure, finance, and advance 
directive-management behaviors related to DTC PGT results.  
Together these three manuscripts support and expand on previous understandings 
about older adults and decision-making in genetics and genomics.  The dissertation 
findings identify many unique qualities of the 60+year old age group while also finding 
similarities that span age groups. These findings support the need for further examination 
of both age-group differences and the phenomenon of genetic or genomic decision-
making.  The differences and similarities among age groups will provide initial findings 
on which future work in decision-making and decision-support can be built. The 
dissertation’s focus on context as a key component of decision-making is both timely and 
forward looking. The need to create unique and informed decision-support interventions 
is growing as the personalized medicine movement begins to bring in more genetic 
information.  Consumer-driven healthcare demands consumer-sensitive approaches. The 
use of behavioral economics and the Protection Motivation Theory as guides will help 
iii 
healthcare professionals to address the age-group differences and the individual contexts 
that shape the genetic decision-making process. 
Keywords: Behavioral Economics, Genetics, Older Adults, Protection Motivation 
Theory. 
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CHAPTER ONE: 
INTRODUCTION 
Exploring the Interface of Genetics, Genomics, and Older Adults 
In the post-Human Genome Project era, as the cost of whole genome sequencing 
is reaching the $1,000 mark, the need for complementary ethical, legal, social 
implications (ELSI) research has increased (Green, Guyer, & National Human Genome 
Research Institute, 2011).  The intersection of technology, health care, and society is one 
that is characterized by constant change; the possibility and promise of new approaches 
to diagnosis, health promotion, and treatment and prevention of disease make genomics 
an important part of improving healthcare.  Ethical, legal, and social implications 
research is imperative in supporting translational genomic science (Green et al., 2011). 
The applications of genetic knowledge to clinical care have changed dramatically over 
the past 25 years and are anticipated to change even more as genetic technology, 
knowledge, and access increase in the future (Catenacci et al., 2015; Green et al., 2011; 
Sobel & Cowan, 2000a).  These changes in applications are happening, not only because 
of the increase in the relative availability of testing, but also because of the growing 
understanding that genetic diseases are family diseases (Forrest et al., 2007; Sorenson, 
Jennings-Grant, & Newman, 2003).  
Published studies addressing families and genetics cover a range of topics 
including risk perceptions, disclosure of results, and effects of results on family (Forrest 
et al., 2007; Lautenbach, Christensen, Sparks, & Green, 2013; Sorenson et al., 2003). As 
an effect of the growing number of older adults who are living longer and engaging with 
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newer healthcare technologies, the family unit, as it has been characterized in the past, is 
in flux (Bookman & Kimbrel, 2011; Seals, Justice, & LaRoca, 2015).  It is important to 
have a general understanding of the familial and generational impacts that genetic testing 
decisions can have through the avoidance or revelation of new genetic information about 
a person and his family (Frazier & Ostwald, 2002).  
The understanding of older adults’ genetic knowledge, genetic perceptions, and 
beliefs is limited.  The few studies that address aspects of older adults in relation to 
genetics tend to highlight low levels of genetic literacy and knowledge among older 
adults and often associate it with lack of exposure to the knowledge in their education 
(Ashida et al., 2011; Carere et al., 2015; Frazier, Calvin, Mudd, & Cohen, 2006; Morren, 
Riken, Baanders, & Bensing, 2007; Ostergren et al., 2015; Skirton, Frazier, Calvin, & 
Cohen, 2005). Other findings regarding older adults and genetics include an increased 
likelihood to defer to clinical expertise of a health care provider rather than to take 
responsibility for the issues related to medical genetic decisions (Frazier et al., 2006) and 
an altruistic and generative quality when considering the possibility of genetic testing 
(Skirton et al., 2005).   While genetic knowledge may be foundational to many other 
tasks related to genetic testing, there are many other factors and influences that must be 
considered with the complex undertaking of making decisions regarding genetic 
information.  
This dissertation is intended to increase current understanding of the perceptions, 
beliefs, attitudes and behaviors of older adults regarding genetic and genomic testing and 
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decision-making, as well as, the usefulness and application of genetic and genomic 
information.  
Problem Statement 
While it long has been understood that any genetic or genomic testing can have 
implications for more than one person (e.g. the information gained from BRCA testing in 
an older adult female with breast cancer, which may affect her three daughters), there is 
limited understanding of how genetic decision-making among older adults is undertaken, 
and how different parties may be engaged in the decision-making processes. Recent 
academic and practice-based discussions about incidental findings demonstrate the need 
for ethical and policy-focused studies of advancing medical technologies.  The inclusion 
of new technologies in healthcare requires finding a delicate balance between doing too 
little, too late and too much, too early.   
As a result of the progression of genomic science and the increasing length of life 
of older adults, it is imperative that research focuses on the implications that genomic-
related decision-making and testing have on older adults and their families. Research 
must address the needs of older adult patients and their adult children (families) as they 
engage in making genetic testing-related decisions (Sobel & Cowan, 2000a).  In order to 
begin to better understand the implications of genetic information on older adult patients 
and their families, further descriptive study is required.   
The knowledge made possible through early descriptive studies is integral to the 
development of future tools and identification of best practices. Much work in genomics 
continues to focus on the younger populations (e.g. incidental findings disclosure, adult-
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onset disease risk disclosure during childhood, parental consent), but very little attention 
has been paid to older adult populations and the potential effects that genomics may have 
on their lives and consequently the lives of their family members. With the rapid growth 
of the older adult population and increased involvement of family in the care of older 
adults, discussions regarding genomics have the potential to affect the older adult-family 
relationship in ways that are unforeseen in younger populations.  
Statement of Significance 
This dissertation will provide important knowledge about older adult patients and 
their perspectives about genomics and genetics as compared with younger age groups.  
The areas of exploration that are key to this study include: the framing of genomic and 
genetic decision-making; the examination of age group differences in genetic knowledge, 
perceptions, and beliefs; the exploration of factors that influence decision-making to 
engage in genetic testing among age groups; and the evaluation of a model for the 
prediction of direct-to-consumer personal genomic testing (DTC PGT) results utilization 
behaviors regarding insurance, finances, retirement, advance plans, and disclosure to 
another person.  
Understanding the differences and similarities of decision-making practices 
among adults of various ages when engaging in personal genetic or genomic testing as 
well as examining their general perceptions, beliefs, and attitudes about genomics will 
provide a valuable foundation on which scientists and clinicians can build tools to aid 
decision-making regarding genetic testing. Additionally, this work has the potential to 
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lead to future policy and practice changes to ensure that older adults’ needs and best 
interests are met and supported. 
Theoretical Framework 
 The guiding theoretical framework for this dissertation is the Protection 
Motivation Theory (PMT) as described by Rogers (Maddux & Rogers, 1983; Rogers, 
1975, 1983).  Originally designed based on the expectancy-value theory with a focus on 
describing the relationships between fear appeals and health behaviors, the PMT is an 
intrapersonal-type theory that supposes that individuals’ abilities to take in, react to, cope 
with, and manage threats or negative outcomes are related to their appraisals of the threat 
and their appraisal of their own coping abilities for dealing with the threat (Floyd, 
Prentice-Dunn, & Rogers, 2000; Rogers, 1983). Scientific applications of the PMT have 
varied since its introduction (Floyd et al., 2000).  The application of the PMT has 
included political and environmental concerns in addition to preventative health 
behaviors, screening behaviors, and disease and injury prevention behaviors. 
Protection Motivation Theory Concepts and Relationships 
The PMT (Maddux & Rogers, 1983; Rogers, 1983), in its revised version, 
features three main concepts: threat appraisal, coping appraisal, and protection motivation 
(Norman, Boer, & Seydel, 2005). The concepts of threat appraisal and coping appraisal 
are better described in the revision of the theory with expansion of the cognitive 
mediating processes that are integral in contributing to related intentions and attitudes 
through the addition of the self-efficacy concept (Floyd et al., 2000; Maddox & Rogers, 
1983; Rogers, 1983).  
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Threat appraisal is best described as the combination of the perceived severity and 
the perceived vulnerability related to the negative outcome of concern (Rogers, 1983). 
This negative outcome could be a disease diagnosis, injury, or some other negative 
experience that can be avoided. Perceived severity is defined in terms of a person’s 
beliefs about the potential bodily harm, interpersonal threats, and intrapersonal threats 
that would result from the negative outcome. Perceived vulnerability is defined in terms 
of a person’s beliefs that they may experience the negative outcome. 
Coping appraisal is described as the combination of perceived self-efficacy and 
response efficacy related to the negative outcome of concern (Maddox & Rogers, 1983; 
Rogers, 1983).  Response efficacy is defined as a person’s beliefs related to the 
effectiveness of coping responses. Self-efficacy is defined as a person’s beliefs about 
their ability to perform or not perform a behavior (e.g., a recommended response to the 
negative outcome of concern). The addition of the concept of self-efficacy is the major 
difference between the initial introduction of the PMT and the revision (Rogers, 1983). 
Protection motivation is best described as the intent to adopt a recommended 
course of action or engage in a protective behavior to limit the likelihood of experiencing 
the negative outcome (Maddux & Rogers, 1983; Rogers, 1975, 1983).  The PMT is based 
on the assumption that there is a positive linear relationship among severity of the threat, 
vulnerability to the threat, the ability to cope with the threat, and that engaging in the 
behavior of concern will decrease risks of the negative outcome (Rogers, 1983). The 
PMT is key in this dissertation work in that it provides a framework for understanding the 
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perceptions that older adults have about genomics, and can offer some insight into their 
individual realities when it comes to managing genomic information. 
Purpose 
In addition to the theoretical framework, the dissertation is guided by three 
primary aims and one exploratory aim: 
Primary Aim 1: Evaluation of behavioral economic concepts as a suitable lens for 
framing decision-making in genetic and genomic testing. 
Research Question 1: What behavioral economic concepts fit genetic and 
genomic decision-making situations? 
Primary Aim 2: Characterize the perceptions and attitudes of older adults regarding 
genetics, genetic testing, and genetic information. 
Research Question 2:  What are older adults’ perceptions regarding genetic 
testing and genetic information? 
Primary Aim 3: Describe the differences in behaviors of genetic testing decision-making 
and application of genetic information among younger and older age groups. 
Research Question 3:  What are the decision-making processes used by older 
adults when making decisions regarding genetic testing and genetic information? 
Exploratory Aim:  Explore the application of the Protection Motivation Theory to genetic 
information disclosure and utilization behaviors among age groups. 
Research Question 4:  What is the relationship among threat appraisal, coping 
appraisal, disclosure of genetic results, changes in healthcare insurance and 
advanced planning behaviors? 
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This dissertation contextualizes decision-making in genetics and genomics with a 
specific focus on older adults in comparison to the other age groups.  These research 
questions are answered through three manuscripts: the first manuscript explores genetic 
and genomic decision-making through the lens of behavioral economics; the second 
manuscript identifies and explores differences in age groups regarding influences on their 
decision to seek personal genomic testing; and, the third manuscript explores the use of 
the PMT to predict disclosure, insurance, retirement, and advanced planning behaviors 
among Impact of Personal Genomics (PGen) participants following receipt of their 
personalized genomic testing results.   
This dissertation seeks to further the understanding of the nature of differences 
among age groups regarding genetic knowledge and perceptions, and add an exploration 
of decision-making, perceived genetic utility, and the influencing factors on the actions 
taken as a result of receiving genetic testing results (e.g. disclosure, adding insurance 
coverage, etc.). The three manuscripts in this dissertation seek to frame the interface of 
genetics, genomics and older adults.  The first manuscript focuses on behavioral 
economics as a lens for understanding decision-making related to genomics.  The second 
manuscript is based on an analysis of the PGen study data examining commonalities and 
differences in the PGen study populations’ genomic perceptions and knowledge and the 
influencing factors that are related to choosing to engage in genomic testing as they differ 
among three age groups (19-39, 40-59, and 60+). The third manuscript explores age and 
PMT as a suitable model for predicting or explaining behaviors related to the use of 
genomic information provided in DTC PGT results.  These three manuscripts together 
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advance the understanding of decision-making in genetics and genomics across age 
groups. 
Methodology 
The three manuscripts chosen for this dissertation are combined to expand current 
understanding of the perceptions, beliefs, attitudes and behaviors of older adults 
regarding genomics, genomic testing, genomic decision-making, and the usefulness and 
application of genetic information.  Exploration and explanation of relationships among 
beliefs and behaviors within and among age groups with regard to genetic information 
will increase the knowledge base needed to better guide decision-making in personal and 
clinical settings.  
 The first manuscript (Chapter 2) entitled “Behavioral Economics: A Lens for 
Understanding Genetic and Genomic Decision-Making,” is a review article that 
introduces three behavioral economic concepts and couples them with appropriate genetic 
and genomic decision-making examples in an evaluation of fit between genetic/genomic 
decision-making and behavioral economics.  In addition to the general overview of 
behavioral economics and the three featured concepts, the manuscript also identifies next 
steps in helping to frame genomic decision-making using behavioral economics. 
 The second manuscript (Chapter 3) entitled “Personal Genomic Testing: 
Understanding Age-Group Differences in Genetic Knowledge, Perceptions, and 
Decision-Making” is a data-based article using the PGen Dataset that examines 
differences among age groups related to perceptions of genomics, genomic knowledge, 
and influences on decision-making related to engaging in genomic testing. This is 
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accomplished through two statistical analysis approaches. First is a comparison of the 
changes between baseline and six-month measures among the three age groups’ genetic 
knowledge, response efficacy, and self-rated competency in genetics. An analysis of 
variance (ANOVA) was used to conduct these analyses. Also, ANOVA was conducted to 
evaluate the changes among the three age groups’ personal utility measures from the 2-3 
week and the six-month follow up surveys. 
 Second, items evaluating ratings of importance for reasons for testing and amount 
of consideration given to decision factors were evaluated first by using factor analysis to 
identify common loading of the factors and then mean scores for each of the two factors 
were compared among the age groups using ANOVA of means. 
 The third manuscript (Chapter 4) entitled “Using Age and Protection Motivation 
Theory to Explore Personal Genomic Testing Result Utilization” is also a data based 
article from the PGen dataset. This article focuses on evaluating the PMT as a model for 
examining the use of genomic testing results looking at similarities and differences 
among age groups. This analysis consists of contingency tables examining age group 
membership and the following PMT concept measures: perceived utility of genetic 
information, genetic knowledge, perceived severity of genetic results, perceived 
vulnerability to genetic illness after getting results, response efficacy after results, and 
self-efficacy after getting results on whether or not a participant chose to discuss genetic 
results, make a change in their healthcare insurance, make a change in their retirement, or 
make a change in their advanced planning behaviors.   
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 The final chapter (Chapter 5) brings the three manuscripts together and attempts 
to contextualize the dissertation findings.  The three manuscripts work to frame the issues 
related to decision-making in genetic and genomic testing among older adults. 
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CHAPTER TWO: 
BEHAVIORAL ECONOMICS: A NEW LENS FOR UNDERSTANDING GENOMIC 
DECISION-MAKING 
Abstract 
 
Behavioral economics has been identified in previous articles as a key component of 
understanding genomics. This article seeks to take the next step in examining the insights 
that can be derived from using them in combination. As genomic science continues to 
permeate clinical practice, behavioral economics will continue to warrant further 
exploration and education for nurses and health care providers. Decisions associated with 
genomics are often not either/or in nature but are complex and may be challenging for all 
involved. These complexities make behavioral economics an interesting option for 
framing our understanding of these decisions. This article offers a brief introduction to 
behavioral economics as a possible tool to help with decision-making related to 
genomics. Behavioral economic concepts that are specifically examined as new ways to 
view the complexities of genomic decision-making include relativity, deliberation, and 
choice architecture.  Each concept is discussed with explanatory examples to help 
understand applicability to clinical practice. The article also explores the next steps and 
practice implications for further development of the behavioral economic lens.   
Keywords: behavioral economics, genomics, decision-making, nursing 
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Behavioral Economics: A New Lens for Understanding Genomic Decision-Making 
Introduction 
 As genomics advances with the development of additional screening and testing 
procedures, it is imperative to understand how the expanding capacities of genomic 
science can be integrated into practice.  Further, as translational science comes to the 
forefront in genomics, scientists and clinicians alike must assess the social, ethical, and 
familial implications of the increased power and availability of genomic testing. Over the 
course of the last 20 years, access to the genome has increased in numerous ways. As a 
result we have more information available to us than ever. These changes require diligent 
work in research and scholarship to ensure that the very best applications are safe and 
equitably available for those affected (Green, Guyer, & National Human Genome 
Research Institute, 2011). 
The field of behavioral economics, the study of forces and principles behind the 
decision-making behaviors of humans, is growing rapidly (Madden, 2000). The field is 
highly focused on economic contexts; however, applications outside of a strictly 
economic environment are promising.  Many opportunities for the application of 
behavioral economics have been aligned with incentivized health outcomes and health 
behavior changes (Bickel & Vuchinich, 2000; Hostetter & Klein, 2013; Hough, 2013). 
These concepts may also prove very useful in helping clinicians better understand 
decision-making of patients in various settings and situations. In the realm of genomic 
decision-making there are several opportunities for the application of behavioral 
economics in clinical practice that bear exploration.  Although recent articles have 
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discussed behavioral economics and genomics, they have not fully explored the 
mechanisms related to genomic decision-making (Blumenthal-Barby, McGuire, & Ubel, 
2014; Blumenthal-Barby, McGuire, Green, & Ubel, 2015).   
It is in the setting of the patient-provider relationship where behavioral economics 
can be valuable. Understanding the relationship as a continuum ranging from laissez faire 
to authoritarian approaches, behavioral economics, when applied to decision-making, can 
help to balance these approaches (Bayles, 2010). Each participant enters into the patient-
provider relationship with an information asymmetry-the health care provider brings the 
expertise and the knowledge of the clinical situation while the patient brings an 
abundance of knowledge about themselves, their desires, their experiences, and their 
lives. Behavioral economics can help to navigate the middle-ground balancing the 
knowledge of the provider with the needs of the decision maker (Hough, 2013). 
Behavioral economic approaches can open the door to conversation, which will allow for 
the identification and elimination of the information asymmetry that often exists in 
genomic decision-making encounters.  This article aims, first, to introduce nurses and 
other health professionals to key behavioral economic concepts, providing genomics-
based examples, and then to explore next steps and practice implications for behavioral 
economics and genomic decision-making for nursing and healthcare. 
Genomic Decision-Making in a Behavioral Economic Context 
 Several key framing concepts from behavioral economics are important for a 
better understanding of the unique and often complex case of genomic decision-making.  
Chiefly, it is important to understand the concepts of relativity, deliberation, and choice 
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architecture to adequately contextualize genetic testing decisions within behavioral 
economics. 
Relativity 
Relativity, a central part of the human decision-making construct, allows for 
understanding the relative advantages of one option compared to others (Ariely, 2009). In 
exploring this concept it is important to note that the comparison must be among similar 
and available alternatives. Genomic testing may offer similar alternatives; for example, 
providers and patients can choose among different panels of genetic tests offering a range 
of levels of information including testing for additional (often related) genomic 
variations.  This choice could be limited by insurance coverage and financial constraints, 
but sometimes a similar choice is available.  However, genetic testing often has no 
alternative for relative comparison, and thus there is no comparable methodology that 
offers the opportunity to find out the same level of information.  
The initial question for those facing decisions about genomic testing is whether to 
test at all.  Absent alternatives, the decision is between knowing or not knowing genomic-
level information and the possibility of that genomic information changing the course of 
care.  In applying relativity to these situations there is an increase in the amount of 
information that is needed, specifically regarding the type, amount, and nature of the 
information provided by the test results and how the results may influence next steps in 
patient care. 
There are situations where there are much more affordable and clinically 
expedient choices that can be made. One example is testing serum cholesterol levels 
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rather than doing genetic testing related to familial hypercholesterolemia (FH).  Current 
guidelines do not recommend genetic screening evaluation of patients for FH due largely 
to cost (Robinson, 2013).  Since there are, currently, no gene-specific treatments related 
to treatment of FH, knowing the specific genotype has limited value, so treatment with 
lifestyle, statins, and close clinical monitoring is still recommended, regardless of 
genetics.  
Another example is the use of regular colonoscopies rather than screening for 
familial polyposis-related genes.  A finding in a colonoscopy may itself lead to further 
testing, but the presence of several polyps does not establish a diagnosis of familial 
polyposis. Those patients who are given results from testing of polyposis-related genes 
might be able to better inform their practice of colonoscopy screenings.  Those with 
genetically confirmed increased risks for familial polyposis would be best served not by 
general screening guidelines regarding regular use of colonoscopies, but by the use of a 
more frequent screening beginning at an earlier age (Syngal et al., 2015). 
These two examples highlight how, in terms of relativity, comparison is very 
important in making genomic testing-related decisions. Currently, the genomic testing 
information has limited influence on the course of treatment for FH; however, with the 
familial polyposis there is a great difference in the screening trajectory for a patient with 
a confirmed increased genetic risk for polyposis.  
A related concept of importance is anchoring, the strong behavioral influence 
produced by first impressions (Ariely, 2009).  While often applied in an economic 
context, where first prices are found to influence willingness to spend a certain amount of 
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money on an item, the concept of anchoring can also be applied to health care decision-
making.  If a patient or a family member has had a positive experience with genomic 
testing, then it might encourage them to engage in genetic testing. If they have had a 
negative experience, then the opposite influence may be observed.  
Deliberation 
Deliberation, the effort by an individual to identify new alternatives, new rules, 
for solving a problem, becomes important when practical problem solving guidelines or 
heuristics-based decision tactics have failed in enabling patients or families to make 
decisions regarding new dilemmas (Montzavinos, 2001).  Identifying prior knowledge 
and available evidence and applying that information when facing new problems is 
central to the idea of heuristic decision-making.  However, as with relativity, decisions 
are taken in context. As the mind seeks these new alternatives, there is opportunity to 
address a problem through “ready-made solutions” or to apply the anecdotal knowledge 
of those who have encountered the same or similar situations in the past (Montzavinos, 
2001, p. 39).  This alternative is viable for decision-making in genetic testing, but it is 
also important to realize that, as with any application of the ready-made solution, the 
context of the individual making the decision may be different from that of the person 
providing the experience supporting the ready-made solution. When heuristics are 
inapplicable or have failed, Montzavinos asserts, the individual resorts to a deliberative 
approach. 
The situation that one person faces in a diagnosis and testing decision is likely to 
differ, subtly or grossly, from the anecdotal solution. Contextually, genomic decisions are 
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rarely identical from patient to patient, even within families. Even though test panels and 
results may be the same for several people, their lives and familial, environmental, 
emotional, and financial contexts vary making the application of ready-made solutions 
difficult or impossible (Sweeny, Ghane, Legg, Huynh, & Andrews, 2014). 
It seems relatively clear that there is limited potential for identifying a simple 
ready-made solution for decision-making in genomics. In this regard, behavioral 
economics may, when applied to the general situation of making decisions regarding 
genomic testing, prove valuable in helping patients to make the best, most informed 
decision, one that best aids patients. The way to best shape these processes must rely 
heavily on choice architecture and requires a clear understanding of several of the 
dynamics at play (Thaler & Sunstein, 2008). 
Choice architecture 
Choice architecture is the art of shaping decisions by supporting pre-existing 
human tendencies through designing choices within a framework that will encourage a 
certain choice.  It is one mechanism that can be explored in attempting to best assist 
patients and families as they engage in genetic decision-making. There is a clear 
difference between choice architecture and ‘manipulation’ in that choice architecture 
merely provides guidance for decision-making without attempting to limit a person’s 
autonomy (Sunstein, 2015). Choice architecture can address some of the external and 
internal contexts of decision-making with regard to genetic decisions. Thaler and 
Sunstein (2008) offer some insight on choice architecture that, when applied to genomics, 
further supports the unique nature of the decisions to be made.   
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The application of choice architecture is very well suited to encouraging patient 
choices regarding wellness and preventive health.  In such situations, choice architects 
employ “nudges” to frame decisions about the most appropriate route as the easiest one 
without limiting options.  There are numerous ways to nudge decision-makers, and often 
the processes are subtle because of their reliance on probable human behaviors; context is 
key.  The scope and level of information involved in decision-making in genomics 
requires further exploration when contemplating nudges and choice architecture.  
Understanding the unique nature of genomic information will help sharpen nudge 
methods but also improve our understanding of their applicability in aiding patient and 
family member decisions – and the ethical implications of employing such methods. Key 
nudge tactics that warrant further exploration in the setting of genomic testing decisions 
include: default choices and mapping (Thaler & Sunstein, 2008). 
Default choices. When no action is taken by the patient in genomic decision-
making, some default choice results.   This can be a slippery slope.  Because the impact 
of genetics can extend beyond the decision maker or patient, it is imperative that any 
default choice be respectful and protective of all parties potentially affected by the 
choice.  If choice architects were to use “nudges” in genetics decision-making to prompt 
a default choice, then perhaps the safest default would be the null, no testing, choice, one 
with the potential to affect the fewest people and not to impose effects on others, 
inadvertently or not.  There are some examples where the default to test, such as the use 
of the newborn screening apparatus to test for a panel of specific genetic variants that can 
lead to disease, is established in law (National Human Genome Research Institute, 2015). 
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In this case, the default is set up to ensure early identification and intervention in patients 
with the selected genetic variants to ensure quality of life. Some of the selected variants 
have potential implications for other people beyond the patient (e.g., the tested child’s 
parents and other family members). The policy is designed to protect the perceived best 
interests of the child in order to affect change through early identification, early initiation 
of treatment, and improvement of clinical outcomes. In other situations, a testing default 
choice is not a logical standard; it would be a nudge that discourages exploring other 
options when faced with a new testing, not ready made, testing decision. At this time, 
because the implications of genetic testing results with regard to patient and family life 
are unclear when testing in older populations, there is no clear path to a default choice for 
later life genetics testing.       
Mapping. Mapping can be used as a way to nudge patients when making 
decisions regarding genetic testing.  Mapping draws on a person’s knowledge and 
experiences to establish, by analogy to prior decision situations, a pathway to a decision 
in previously unexplored territory. However, as with most attempts to help shape a 
decision, there are some drawbacks.  Not all genetic testing may lend itself directly to 
mapping, so it is important to be aware of the variables that may limit the ability to map 
out a decision pathway.  These variables, fairly consistent in genomic decision-making, 
include the context and timing of the decision, healthcare provider biases toward one type 
of testing or toward not testing at all, information asymmetry creating an increased 
patient dependence on providers for appropriate information, and the social-emotional, 
and financial “costs” of genetic testing. Those patients and families considering genetic 
   
21 
 
testing may need more time to make decisions, increased knowledge sharing between 
providers and patients and families to limit information asymmetry, and an opportunity 
for deeper exploration of implications with patients to ensure that post-testing effects on 
patient and family lives are at least acknowledged if not mitigated in some way.   
The BreastCARE intervention studies (Kaplan et al, 2014; Livuadais-Toman et al, 
2015) provide an excellent example of how mapping might be helpful with genomics.  
BreastCARE sought to increase awareness and communication among patients and 
providers by using appropriate and validated measures of risk for breast cancer to 
structure a risk-assessment intervention.  This strategy helped to increase communication 
of breast cancer-related information without increasing concern among patients.  This 
intervention did not lead to a genomic testing decision per se, but it used existing 
knowledge to help shape the decision to speak with a provider about breast cancer. Those 
who undergo this intervention may, in turn need, to be assisted in making the decision to 
seek testing for the genes associated with breast cancer, and this too could be mapped 
using a similar intervention. 
Next Steps for Behavioral Economics and Genomic Decision-Making 
As genomic testing becomes more main stream and as more people are faced with 
making decisions about testing and results, it will bring new challenges to old procedures 
and policies. Studies of decision-making processes and concerns and of ways to facilitate 
decisions about testing that account for the various stakes of patients and families will be 
crucial in adapting existing processes and developing new approaches.  Examining 
genetic decision-making through a behavioral economic lens allows for the exploration of 
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the nuanced factors in play for patients and their families in this rapidly emerging field.  
Work must be begun to characterize the decision-making processes undertaken by 
patients, family caregivers, and their healthcare providers in an effort to provide context 
for future studies of behavioral economic approaches in facilitating and shaping the 
decision-making process. While the personal and varied nature of genetic information 
makes restrictive and finely detailed descriptions of processes used in genomic decision-
making less likely, there is a need to have a clearer understanding of any processes that 
are undertaken. 
Incorporation of the elements of behavioral economics can also help to create a 
positive decision-making environment for those who are faced with these often difficult 
genetic testing decisions.  As explored here, genomic testing is unique among medical 
tests because of the nature of the information and the current lack of alternatives available 
to get the same information. This unique nature makes the application of behavioral 
economics and choice architecture techniques to be of some value, but studies identifying 
ways to better support decision-making are imperative.  Understanding if there is a 
decision pathway or some other tool that could be used to help patients consider the 
multiple variables of genomic testing is key for future steps in supporting patient 
decision-making.  
An appreciation of the mechanisms involved in behavioral economics can assure 
that deciders are not forced into particular choices by the contextual forces that can 
disproportionately influence important decisions resulting in a choice that may not fully 
reflect a patient’s values or represent a full deliberation of the situation.  Behavioral 
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economics does not rest solely on the belief that humans will always act rationally in a 
given situation, but rather accounts for contextual influencers such as emotions, cognitive 
biases, and other internal and external pressures (Ariely, 2009).  There must, therefore, be 
a better understanding influence of the social, emotional, and financial costs has on 
medical decision-making, and more specifically genomic decision-making. There is a 
wide range of variables that each person will uniquely encounter, but there are also many 
commonalities that must be accounted for and further explored (Lerner, Li, Valdesolo, & 
Kassam, 2015).  One behavioral economic concept that has been noted is the present-
centeredness, termed “present bias,” that shapes decision-making (Hostetter & Klein, 
2013). Awareness of present bias is important in understanding how costs are perceived 
when making decisions.  Understanding the value of information at the moment of testing 
and understanding the possible implications for future decisions of the patient and the 
patient’s family is imperative in assisting with decision-making. 
It is important to consider how behavioral economic concepts can be applied in 
clinical practice.  In the current patient-centered care environment, nursing has a unique 
role in patients’ decision-making processes.  Relationships with patients and their 
families in times of illness and wellness place nurses in the context of making important 
decisions.  Often nurses are seen as a source of information and clarification when 
communication with physicians or specialists is limited.  Nurses and other healthcare 
professionals must seek to better understand the context of the care that they are 
delivering to their patients. The behavioral economic concepts described in this article 
offer a good start for better understanding decision-making, specifically in a genomic 
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context. Beyond the genomic focus of this article, nurses can benefit from further 
exploring these concepts, understanding how their own practices may inadvertently 
influence patient and family decisions, and incorporating some of these approaches in 
supporting patients and families as they make difficult decisions.  
 While these behavioral economic concepts do bring a new lens to the work that 
must be done regarding genetic decision-making, they do not replace the key concepts 
that are embodied in high quality health care provision.  It is important to keep these 
professional and ethical standards in mind as decision-making work is undertaken.  
Patients are more than the sum of their complaints, diseases, or syndromes, and the 
process of diagnosis and treatment of illness is complex and multifaceted, possibly even 
more so when genomics are involved (Gorovitz, 2010). The use of the behavioral 
economic mechanisms to support patient decision-making is helpful in managing the 
complexities of these decisions through the use of information and expertise while still 
respecting autonomy of patients and families.  This is the essence of the marriage of 
behavioral economics with the patient-provider relationship—the use of these approaches 
to overcome the asymmetry of information that often exists through thoughtful and 
deliberate support of patient decision-making. 
Continued interdisciplinary, collaborative exploration of decision-making is an 
important part of assuring that patient decision-making with regard to genomics is 
supported to the highest possible level.  Understanding the core concepts of behavioral 
economics and choice architecture is key in this endeavor, and the use of these concepts 
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to inform future studies will allow for improvement of the patient experience in genomic 
decision-making. 
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CHAPTER THREE: 
 
PERSONAL GENOMIC TESTING: UNDERSTANDING AGE GROUP 
DIFFERENCES IN GENETIC KNOWLEDGE, PERCEPTIONS, AND DECISION-
MAKING 
 
Abstract 
Purpose of The Study: This study describes differences among three age groups (19-39, 
40-59, 60+ years old) who are new customers of direct-to-consumer personal genomic 
testing (DTC PGT) in their knowledge and perceptions of genetics as well as factors that 
influence their decisions to test.   
Design and Methods: This analysis of the Impact of Personal Genomics Study used a 
sample of 887 study participants who were surveyed three times via online survey 
(baseline [before receiving results], 2-3 weeks after receiving results, and 6 months after 
receiving results).  ANOVA was used to evaluate change in means of Genetic 
Knowledge, Self-Rated Genetic Competency, Personal Genetic Utility, and Genetic 
Response Efficacy over time and also across the three age groups. Factor analysis was 
used to identify factors related to the decision to engage in DTC PGT.  
Results: For Genetics Knowledge and Personal Genetic Utility scores, the 60+ year old 
group had significantly lower scores when compared with the other two age groups.  
Factor analysis identified two strongly loading factors with themes of ‘Health and Future’ 
and ‘Curiosity and Intrigue’ oriented items.  There was a significantly lower mean ‘health 
and future’ score among the older adult population. 
Implications: While the sample for this study was drawn from DTC PGT customers, 
these results support previous understandings that older adults have different views of 
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genetic and genomic testing than the younger age groups.  Differences among the age 
groups support the need for further study and evaluation of approaches to meet the unique 
needs of older adults when it comes to genomic testing and understanding the value and 
use of genomic results.  As the aging population grows and their care is guided by 
genomic testing, these areas of age group differences may hold a place in helping to 
design interventions to support and engage older adults in their precision care. 
 Keywords: decision factors, genetic testing, genetic knowledge, older adults 
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Personal Genomic Testing: Understanding Age Group Differences in Genetic 
Knowledge, Perceptions, and Decision-Making 
 
Introduction 
The drive to make healthcare a personalized, precision science means that 
individual complexities will be very influential in tailoring interventions.  Genomics and 
genetics are part of the science that will shape the personalization of medical care. As 
work in health sciences moves closer to precision medicine, the personal context in which 
healthcare encounters occur is becoming more important (Bayliss et al, 2014). 
Understanding the contextual factors and influencers of patient decision-making 
behaviors is an important part of understanding personal contexts and is key in helping to 
support patient decision-making.  While underlying genetic knowledge is important, the 
existence of other contextual factors such as perception of genetics, response efficacy, 
and genetic utility may also offer some important insight into decision-making. The 
purpose of this study is to explore differences among three age groups in genetic 
knowledge, perceptions, and decision-making influencers. 
There has been limited study specifically about the knowledge and perceptions of 
older adults related to genetics and genomics. Among those few studies, older adults have 
demonstrated a willingness to participate in genetic testing if it demonstrates value and 
has promise for illness prevention or benefit for future generations (Skirton et al., 2005). 
Older adults also identified the importance of family involvement and clarity of testing 
purpose (Frazier et al., 2006).  Several quantitative studies have reported some age-
related differences with regard to knowledge and beliefs. Older adults have been found to 
have lower genetic knowledge scores when compared with other age groups (Ashida et 
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al., 2011; Carere et al., 2015; Morren et al., 2007). Additionally, some differences in 
beliefs about genetic causes of weight and obesity have been associated with differences 
in age (Ashida et al.). A significantly lower comprehension of genetic results has been 
noted among older adults when compared with younger adult groups (Ostergren et al., 
2015).  
Genetic Decision-Making 
An understanding of how decisions are made regarding genetic testing can help 
health care providers and genetic counselors improve their facilitation of patient and 
family decision-making. In the early years of prenatal diagnosis and pre-conception 
genetics, clinical professionals and medical ethicists identified the need to support 
individualized decision-making related to genetics (Pauker, 2013; Paulsen et al., 2013). 
The research-based descriptions of decision-making of patients with regard to predictive 
genetics addressed ideas and questions, such as: How has a treatment option been 
developed? Is treatment curative or palliative in nature? If treatment is unavailable, does 
testing offer some opportunity to decrease ambiguity?  Does genetic information impact 
reproduction decisions? Could genetic information assist other family members? 
(Henderson, Maguire, Gray, & Morrison, 2006; Katz, Kurian, Morrow, 2015; Paulsen et 
al.).  
  The study of decision-making is very common in gene-linked cancer diagnosis 
and treatment (Iredale et al., 2008; McQuirter et al., 2010; Sames, 2008).  The 
understanding of gene significance in hereditary breast cancer has brought increased 
focus on decision-making and decision aids for patients with BRCA1 and BRCA2 
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mutation-linked familial breast cancer.  In Iredale, et al.’s study, the complexity of 
decision-making and familial breast cancer changes as the level of risk changes for the 
patient. A common element, however, was a desire for discussions of preventive and 
lifestyle related information that does not offer false hope (Iredale, et al., 2008).  The 
desires of the participants (breast cancer patients) for specific types of information were 
also different when compared among risk-groups. The participants were sensitive to their 
own concerns and also the perceived preferences of healthcare professionals when 
choosing among treatments.   While these tests are more targeted, education about risks 
and limitations regarding genetic analysis of the whole genome helps to decrease 
uncertainty and decisional conflict (Sanderson et al., 2013). 
Familial linkage and the witnessed experiences of their relatives’ having cancer 
are driving factors for making the decision to seek out prophylactic mastectomy as a 
method of seeking control among people at risk for breast cancer (McQuirter et al., 
2010).  The process is unique to each woman, because of her previous experiences and 
her life situation at the time of making the decision (McQuirter et al.). Multiple concerns 
influence patient decisions, including previous personal or familial experiences with 
cancer; and the desire to have some control over decisions, personal image, provider 
recommendation, and support. While some of these concerns are truly specific to 
mastectomy decisions, many can be generalized to the population of patients with 
BRCA1 and BRCA2 mutations at the very least.  Focusing on a treatment decision in 
response to genetic findings, McQuirter and colleagues offer insight into the same areas 
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of concern (e.g., the value of testing; influence on family members) other patients 
contemplating genetic testing or facing unfavorable genetic results may encounter.  
While there has been a strong history of paternalistic directives by health care 
professionals in genetic decision-making, there is an increased involvement of patients in 
decisions related to genetic testing.  In the study of cancer, specifically breast cancer 
diagnoses, there is an increased reliance on patient preferences (Katz et al., 2015).  One 
important aspect of increased patient involvement is ensuring that patients are aware and 
accepting of the extended implications of the genetic information on patients’ relatives 
and possibly future cancer diagnoses.  This increased involvement of patients is also 
associated with an increased use of genetic technologies in patient care across multiple 
cancers, not just limited to breast cancer.  
Decision-Making Among Older Adults 
Gerontologists and geriatricians encourage preservation of autonomy and control 
in older adult patients (Mallers, Claver, & Lares, 2014). When older patients are 
supported in maintaining control over decisions, they are more successful through the 
aging process and have better outcomes (Mallers et al.).  The study of decision-making in 
older adults is emerging on the health care forefront. In light of the importance of 
autonomy to older patients, an emphasis to better understand the value older adults place 
on shared decision-making in the health care setting is needed. The underpinning 
concepts of shared decision-making (e.g., information exchange, deliberation regarding 
preferences, and developing agreement between patient and provider) were very similar 
to the desires that the older adults had for their interactions with providers (Burton et al., 
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2015; Naik et al., 2005). The level of information sought varies by patient; however, most 
favor the provision of limited amounts of information (Burton et al.).  Deliberative 
capacities have been found to be lower among older adults than younger adults when 
dealing with new information; however older adults demonstrated a preservation of 
affective abilities when dealing with experience based decision-making (Huang, Wood, 
Berger, & Hanoch, 2015).  
In summary, the current understanding of genomic decision-making among older 
adults is limited. The differences among the age groups that have been identified are in 
genetic knowledge and perceptions of gene-obesity linkages. Genetic testing decision-
making has, in general, been found to be associated with the level of information and 
provider perspective, but there are limited studies of the older adult populations with 
regard to genetic decision-making.  In general, it is important for older adults to be 
involved in their own decision-making; however, older adults may need more support 
when they engage in information processing and decision-making related to costs and 
benefits and are presented with information about a new or unfamiliar decisional 
situation.  
While genetic knowledge has been shown to differ among age groups, the other 
contextual factors and motives that influence decision-making may also differ among age 
groups. There are no studies that explore those differences across the age groups. In this 
study we sought to investigate these age differences by answering two questions through 
secondary analysis of the Impact of Personal Genomics (PGen) data: 1) What are older 
adults’ perceptions regarding genetic testing and genetic information as compared to 
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other age groups? 2) What influences decision-making of older adults when deciding to 
engage in direct-to-consumer personal genomic testing (DTC PGT) as compared to other 
age groups? 
Design and Methods 
 The PGen study was approved by the Partners Human Research Committee and 
the University of Michigan School of Public Health Institutional Review Board. Each 
participant completed an electronic informed consent prior to being enrolled.  Details of 
design and data collection for the PGen study have been reported previously (Carere et 
al., 2014; Lehmann et al., 2012). 
 The sample was recruited between March and July 2012 from new customers of 
23andMe and Pathway Genomics, two independent DTC PGT agencies, after they placed 
an order for genomic testing. Participants in the study were asked to complete three 
online surveys administered by Survey Sciences Group (Ann Arbor, MI).  The three 
surveys included a baseline survey which was administered after submission of the 
sample but prior to receipt of DTC PGT results, two to three week follow up after receipt 
of DTC PGT results, and six-month follow up after receipt of DTC PGT results.  
Sample 
 The total sample for the PGen study included 1,464 participants who engaged in 
DTC PGT. The sample used for this study consisted of the 887 participants who 
participated in all three of the surveys and completed all analyzed items and scales. These 
887 participants were split into three age groups, 19-39 year olds, 40-59 year olds, and 
60+ year olds. This division was based on other studies with the data set (Ostergren et al. 
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2015). Demographic characteristics for the 887 individuals included in our study are 
depicted in Table 3.1. 
Table 3.1  
Demographic and Socioeconomic Characteristics by Age Group (%)  
Age Group (years) 19-39  40-59  60+  Overall 
Number 
Mean Age (years) 
Female  
Relationship status 
   Single 
   Married/Partnered 
   Divorced/Separated/Widowed 
Adopted 
Have Biological Children 
Ethnicity 
   Hispanic/Latino 
Racea 
   Asian 
   Black or African American 
   White 
   Other Race 
Highest Level of Education 
   Less Than College 
   College Degree 
   Some Graduate School 
   Doctoral Equivalent 
Income in the past 12 Months 
   <$100,000 
   $100,000-199,999 
   ≥$200,000 
350 
30.22 
56.9 
 
36.3 
58.6 
5.1 
6.0 
18.9 
 
6.9 
 
9.7 
3.7 
86.6 
11.9 
 
17.2 
37.1 
35.1 
10.5 
 
58.9 
29.1 
10.0 
314 
49.51 
64.1 
 
14.6 
71.5 
14.0 
7.9 
60.6 
 
5.1 
 
2.2 
3.8 
92.4 
7.0 
 
20.7 
31.1 
34.2 
14.0 
 
48.4 
36.3 
15.3 
223 
66.92 
56.1 
 
5.4 
75.8 
18.9 
2.2 
78.5 
 
1.3 
 
0.0 
1.3 
95.5 
7.1 
 
25.1 
17.9 
40.0 
17.0 
 
58.4 
28.1 
13.6 
887 
46.28 
59.2 
 
20.8 
67.4 
11.7 
5.7 
48.6 
 
4.8 
 
4.6 
3.2 
90.9 
9.0 
 
20.4 
30.2 
36.0 
13.5 
 
55.9 
31.4 
12.8 
Note: aSome participants indicated more than one race thus the totals exceed 100%. 
Measures  
The major variables of interest in this study include: Genetic Knowledge (GK), 
Self-Rated Genetic Competency (SRGC), Genetic Personal Utility (GPU), and Genetic 
Response Efficacy (GRE). The term genetic knowledge describes the factual science, 
familial inheritance, and technology information related to genetics and genomics as it is 
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known to the respondent.  In this study, genetic knowledge is measured using a nine-
item, true or false instrument that is a combination of selected items from previous 
studies of genetic knowledge (Bowling et al., 2008; Furr & Kelly, 1999; Molster, 
Charles, Samanek, & O’Leary, 2009; Smerecnik, 2010). Genetic knowledge is measured 
at baseline and at the six-month follow up, and is expressed as a percentage of correct 
answers. 
The SRGC Scale is composed of five seven-option Likert type items that evaluate 
a respondent’s beliefs in their own ability to understand genetic information. The SRGC 
Scale was administered at baseline and at the six month follow up, higher scores indicate 
stronger beliefs in their own abilities. The Genetic Personal Utility Scale (GPUS) is 
composed of three questions with a five-option Likert-type scale (Bloss et al., 2010). 
These GPUS questions are asked in the two to three week follow up and six-month 
follow-up questionnaires. The GPUS questions address a respondent’s perception of the 
usefulness of the genetic testing results regarding their health.  Higher scores indicate a 
greater perceptions of usefulness.  A five-option Likert-type single item is used to 
measure GRE in respondents (Wade et al., 2012). The item is included in the baseline and 
six-month follow-up questionnaires, a higher score indicates greater belief that genetic 
testing has benefits for improving or maintaining health.  
Statistical Analysis 
 A mixed between-within subjects, repeated measures analysis of variance 
(ANOVA) was used to compare the changes between initial and follow-up measures of 
Genetic Knowledge, Genetic Response Efficacy, Self-Rated Genetic Competency, and 
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Genetic Personal Utility among the three age groups. When homogeneity of covariance 
was not satisfied, Pillai’s Trace was used to increase the robustness and power of the 
analysis. Bonferroni corrections were conducted for post hoc analyses when appropriate. 
In order to identify genetic testing decision-making influencers, participant ratings 
of importance for 19 aspects of genetic testing were evaluated by factor analysis with 
Oblimin (Oblique) rotation to identify any scoring patterns among the sample. The means 
of the three age groups for the resulting factors were compared using ANOVA. When 
homogeneity of variance was not satisfied, Welch’s adjusted F ratio was evaluated, 
correcting for inequalities in variance among groups (Welch, 1951). In addition, Games-
Howell post hoc tests were performed using an a priori alpha level of .05. Analyses were 
conducted using IBM SPSS Statistics, Version 23.0. 
Results 
Descriptive statistics for Genetic Knowledge, Self-Rated Genetic Competency, 
Genetic Response Efficacy, and Genetic Personal Utility are presented in Table 3.2.   
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Table 3.2  
Genetic Knowledge, Perceptions, and Beliefs Descriptive Statistics by Age Group  
Scale 19-39 years 40-59 years 60+ years Overall 
Genetic Knowledge      
   Baseline 92.00 (9.56) 90.90 (10.69) 88.99 (11.16) 90.85 (10.44) 
   6 month follow-up 92.95 (9.28) 91.85 (9.54) 89.89 (11.46) 91.79 (10.02) 
Self-rated Genetic  
   Competency 
    
   Baseline 5.80 (1.17) 5.85 (1.13) 5.81 (0.97) 5.82 (1.10) 
   6 month follow-up 5.63 (1.10) 5.59 (1.11) 5.35 (1.05) 5.55 (1.09) 
Genetic Personal  
   Utility  
    
   2-3 week follow-up 3.96 (0.77) 3.92 (0.86) 3.76 (0.98) 3.89 (0.86) 
   6 month follow-up 3.69 (0.90) 3.77 (0.95) 3.58 (1.05) 3.69 (0.96) 
Genetic Response  
   Efficacy 
    
   Baseline 3.49 (0.98) 3.43 (0.97) 3.37 (0.94) 3.44 (0.97) 
   6 month follow-up 3.23 (1.05) 3.42 (1.09) 3.22 (1.13) 3.30 (1.09) 
Note: Values expressed as Mean (SD) 
 
Comparing Genetic Knowledge and Perceptions Measures Among Age Groups 
There was not a significant interaction between time and age group membership 
on genetic knowledge scores, F (2, 885) = 0.002, p = .998.  There was a significant effect 
of time on genetic knowledge, F (1, 886) = 5.749, p = .017. All of the age groups showed 
an increase in genetic knowledge scores between the baseline and six month follow-up 
surveys. Age group membership had a significant effect on differences in genetic 
knowledge scores, F (2, 885) = 8.862, p < .001. Post hoc analyses indicated a significant 
difference in change in genetic knowledge scores when comparing the 60 + year old 
group with both the 19-39 year old group (M=.274, 95% CI [.118, .430], p<.001) and the 
40-59 year old group (M=.174, 95% CI [.015, .334], p<.05).  
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There was a significant interaction effect for time and age group membership on 
SRGC, F (2, 885) = 4.169, p = .016. Post hoc tests show no difference in means between 
the 19-39 year old and 40-59 year old groups (M=.000, 95% CI [-.173, .172], p=1.00) 
while there was a difference between the 60+ year old group and the 19-39 year old 
group (M=.135, 95% CI [-.325, .055], p<.269) and the 40-59 year old group (M=.135, 
95% CI [-.329, .059], p<.288). There was also a significant effect of time on SRGC, F (1, 
886) = 55.159, p<.001. All of the SRGC scores decreased over time regardless of the age 
group. Age group membership was not significant, F (2, 885) = 1.772, p = .171.  
There was also a significant interaction effect for time and age group membership 
on GRE, F (2, 885) = 3.523, p = .030. The main effect for time on GRE was significant, 
F (1, 886) = 11.175, p = .001. Genetic Response Efficacy scores were higher at baseline 
than they were after six months, regardless of age group.  There was no significant main 
effect for age group membership on GRE, F (2, 885) = 1.705, p = .182.  
The interaction effect for time and age group membership on GPUS was not 
significant, F (2, 885) = 2.045, p = .130.  However, there was a significant effect for time 
on GPUS, F (1, 886) = 59.450, p < .001, the scores for GPUS were higher at the two to 
three week survey than at the six month follow up.  There was also a significant effect for 
age group membership, F (2, 885) = 3.307, p = .037. There were significant differences 
between the 60+ year olds and both the 19- 39 year olds (M=.155, 95% CI [.016, .294], 
p<.029) and the 40-59 year olds (M=.174, 95% CI [.031, .316], p<.017), indicating that 
the GPUS scores for the 60+ year olds were significantly lower than both of the other age 
groups. 
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Examining Patterns in Decision-making Influences 
The 19 items that focused on reasons to test and factors influencing testing 
decisions were subjected to factor analysis. The screeplot illustrated a clear break after 
the second factor.  Using Catell’s (1966) scree test, it was decided to retain two factors 
for further evaluation.  Table 3.3 illustrates the pattern and structure matrices for the two-
factor solution with a 0.4 pattern coefficient cut off.  
The two-factor solution explained a total of 32.8% of variance, with Factor 1 
contributing 22.3%, and Factor 2 contributing 10.5%. The rotated solution revealed the 
presence of simple structure (Thurstone, 1947), with both factors showing a number of 
strong loadings and each variable loading substantially onto only one factor. 
The interpretation of the two factors identified two unique patterns to the 
loadings.  Items focused on health and the future loaded strongly onto Factor 1.  Items 
more aligned with the curiosity and intrigue of genetics loaded strongly onto Factor 2. 
There was a weak correlation between the two factors (r = .203).  These results suggest 
that the components can be evaluated separately. Two factor scores were created by 
averaging the items from each factor. 
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Table 3.3  
Pattern and Structure Matrix for Factor Analysis with Oblimin Rotation  
 
Survey Item 
Pattern 
coefficients 
Structure 
coefficients 
Communalities 
 Factor Factor 
 1 2 1 2 
H
ea
lt
h
 a
n
d
 F
u
tu
re
 
 Improve my health .812 -.052 .801 .113 .645 
 Create a better plan for the 
future 
.780 -.033 .773 .125 .598 
 Finding out about personal risk 
for specific diseases 
.779 -.134 .769 .150    .583 
 Health-related .771 -.007 .752 .024 .592 
 Predict whether or not I'm going 
to get a particular disease 
.693 -.018 .689 .122 .475 
 Individual response to different 
types of medications 
.680 -.003 .679 .135 .461 
C
u
ri
o
si
ty
 a
n
d
 I
n
tr
ig
u
e 
 Personal interest in genetics in 
general 
-.098 .557 .015 .538 .298 
 The convenience of being tested 
at home 
.037 .526 .143 .533 .286 
 The education materials made 
available through the company 
.116 .508 .219 .531 .295 
 Desire to learn more about my 
genetics because I am adopted 
.118 .494 .218 .518 .282 
 Curiosity about my genetic 
makeup 
-.081 .478 .016 .462 .219 
 The service seemed like it would 
be fun and entertaining 
-.311 .455 .345 .447 .247 
N
o
n
-L
o
ad
in
g
 
 Might receive unwanted 
information 
.372 .078 .419 .378 .156 
 Information about the risk for my 
current or future children 
.358 .305 .388 .153 .265 
 Privacy of my genetic information .227 .128 .253 .174 .080 
 Other members of my family are 
using personal genomic services 
.021 .396 .297 .415 .161 
 Learn about my genetics because I 
have limited information about 
family health history 
.266 .394 .101 .400 .268 
 Learn about my genetic makeup 
without going through a physician 
.222 .369 -.219 .392 .219 
 Cost of services -.018 .321 .047 .317 .101 
Note: Major loadings for each item included in factors are bolded. 
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Age group membership was examined for the two factors using ANOVA. 
Descriptive statistics for each of the factors for the age groups and overall are found in 
Table 3.4. Though the assumption of homogeneity of variance was not satisfied. The 
effect of age group membership was significant, Welch’s F (2, 513.34) = 5.012, p < .01. 
Post hoc tests indicated that the mean scores for the 60+ year old age group were 
significantly different from the 19-39 year old and 40-59 year old groups for the Health 
and Future Factor (p = .006 and p = .028 respectively). There was not a significant 
difference in the Curiosity and Intrigue scores for the three age groups: F (2, 884) = 
2.011, p = .134. 
Table 3.4  
Descriptive Statistics for Two Factors by Age Group 
 19-39 years old 40-59 years old 60+ years old Overall 
Health and Future  2.37 (0.46) 2.36 (0.51) 2.23 (0.60) 2.33 (0.52) 
Curiosity and Intrigue        2.47 (0.40)       2.41 (0.41) 2.47 (0.41) 2.45 (0.41) 
Note. Values expressed as Mean (SD) 
Discussion 
 When examining the differences among age groups related to genetic knowledge, 
perceptions, and factors that shape decision-making there are differences between the 60+ 
year old group and the younger age groups.  Older adults were found to have significantly 
lower genetic knowledge scores, and age group membership was also found to be a 
significant factor in differences in perceptions of genetic utility. Self-rated genetic 
competency, and genetic personal utility measures had significant decreases over time, 
while Genetic Knowledge increased significantly over time. Thus there were differences 
in perceptions of genetics among older adult participants in the PGen study when 
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compared with other age groups. The factors that influenced the decision to engage in 
DTC PGT loaded into two factors, ‘Health and Future’ and ‘Curiosity and Intrigue.’ 
Older adult groups had significantly lower scores in the ‘Health and Future’ factor, 
indicating that older adults may be less likely to be concerned with the ‘Health and 
Future’ aspects of testing than the other age groups. This may be an effect of fatalism on 
the part of older adults, or perhaps they do not place a high value on the future 
possibilities for genetic information on their own health. 
 The results of this study further support previous studies’ assertions that there are 
clear differences in genetic knowledge among different age groups (Ashida et al., 2011; 
Carere et al., 2015; Morren et al., 2007; Ostergren et al., 2015).  The results of 
comparisons of genetic knowledge show that the 60+ year olds were more likely to have 
statistically significant lower genetic knowledge scores than the other two groups.  As 
previously discussed, these findings could be associated with limited genetics education 
exposure even with 57% of this age group reporting having had some graduate education.  
These results must be examined in the overall change that is exhibited in knowledge, the 
change is scores, while statistically significant, is not necessarily a meaningful change as 
it is small in comparison to the overall scoring for the genetic knowledge questions. Even 
in light of this, the finding highlights the need to seek out opportunities and methods to 
educate older adults about genetics so that they are better able to engage with the genetic 
technology that is becoming more available in society clinically and commercially.   
The decreases of the Self-Rated Genetic Competency scores over time may 
indicate that the experience of using DTC PGT may have led the participants to 
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reconsider their abilities to interpret the genetic material. Response Efficacy measures 
also decreased over time, possibly indicating that the receipt of the DTC PGT results may 
have caused the study participants to change their views on the ability of genetic level 
information to improve their health.  This change could also be related to the fact that 
their DTC PGT results may not have any genomic findings that were new to the 
participants or that they felt like they could do anything about after receiving the results. 
 There was also a statistically significant decrease in the respondents’ GPUS 
scores. The decrease of the means of these scores across all three age groups does suggest 
that there may be a feeling of inability to connect the PGT results directly to health 
actions among all age groups. Further study is needed to better understand this 
possibility.  It would be very interesting to understand if the decrease in the personal 
utility scale scores relates to specific factors or is the decrease a result of a failure to meet 
the participants’ anticipated utility prior to receiving the results.  
While understanding the knowledge and perception differences among the three 
age groups is helpful, in order to move a step closer to the actual decision-making 
process, it is important to understand the driving motivations for engaging in DTC PGT. 
The identification of the two factors capturing the participants’ reasons to test is 
important because it highlights two distinct areas of interest that were unique among the 
participants.  The Health and Future-Oriented factor was the stronger loading factor, 
highlighting the importance that participants placed on the health-related aspects of the 
genomic testing.  The second factor is best characterized as being Curiosity and Intrigue-
Oriented which captures the elements of DTC PGT that are more related to the novelty 
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and, to some extent, recreational engagement that some participants find most appealing.  
When these two factors are compared across the age groups, the 60+ year old group was 
significantly less likely to rate the Health and Future-related aspects of DTC PGT as high 
as the other two age groups were.  This finding may be tied with the differences seen in 
the genetic knowledge score among the age groups; however, it is also possible that there 
are other factors of importance to older adults that were not captured by the surveys.  
When looking at the second factor scores, ‘Curiosity and Intrigue,’ there is no statistical 
difference among the three age groups.  This may be a result of the fact that this test is 
not being completed in a clinical setting and that the aspects captured by this factor are 
baseline aspects that all participants in DTC PGT find important.  Both of these factors 
could be examined more completely in an effort to fully understand what drives 
participants to engage in the DTC PGT.  
 The use of the PGen data set provides great benefits in providing a high quality 
repeated measures survey study with a large sample of respondents for the exploration of 
these questions, although it should be noted that there are several limitations of the study 
that must be acknowledged.  First and foremost, these results give some insight into the 
different age groups, but they are somewhat limited in their broader application because 
of the fact that the sample is predominantly white (90.9%), married/partnered (67.4%), 
largely female (59.2%) and affluent (44.1% reporting annual earnings > $100,000).  It is 
also imperative to realize that the entire sample is self-selected. Translation of these 
findings will require other study designs, more diverse populations, and comparisons of 
the findings to better support generalizable research findings. 
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In conclusion, there are significant differences in the genetic knowledge and 
perceptions of the 60+ year old age group when compared with the 19-39 year old and 
40-59 year old age groups.  These differences, even while observed in this group of DTC 
PGT participants, offer some clear indications that more research on the older adult 
population with regard to genetics and genomics knowledge, perceptions, and decision-
making needs to be done.  Furthermore, there is a need for similar studies to examine 
those persons who are engaging in clinical genetic or genomic testing programs beyond 
DTC PGT.    
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CHAPTER FOUR: 
 
USING AGE AND PROTECTION MOTIVATION THEORY TO EXPLORE 
PERSONAL GENOMIC TESTING RESULT UTILIZATION 
 
Abstract 
 
Background:  Direct-to-consumer personal genomic testing (DTC PGT) is changing the 
way that people are able to access genetic level information.  Testing results from DTC 
PGT companies come in a different format than those from clinical testing and healthcare 
providers.  Consumers who use DTC PGT are getting the genetic-level information and 
are sometimes making social and financial health-related decisions based on their own 
perceptions of the meanings of the results. 
Objectives:  To explore the use of the Protection Motivation Theory (PMT) concepts as a 
way to better understand behaviors of results utilization in DTC PGT customers through 
looking at trends among three age groups. 
Methods: We analyzed data from the Impact of Personal Genomics Study, which were 
collected before DTC PGT results were received, and again at two to three week and six 
month follow-up intervals following participants’ receipt of DTC PGT results. 
Contingency tables and descriptive statistics were used to examine trends in PMT 
concepts and uses of DTC PGT results among three age groups.  Four outcomes were 
examined: 1) discussing DTC PGT results with someone, 2) making changes in health 
insurance, 3) making changes in financial or retirement plans, and 4) making changes in 
advance planning. 
Results:  Those who engaged in making changes to their retirement and advance 
directives were more likely to be of the 60+ group than any other group.  There were no 
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large differences in the ratings of the PMT theory concepts, those who engaged in the 
four target behaviors were more likely to have higher response efficacy and self-efficacy 
ratings while having moderate to lower perceived severity ratings and moderate to higher 
perceived vulnerability ratings. 
Conclusions: The significance of the application of the PMT is valuable in helping to 
better understand who and, possibly in the future, why some DTC PGT participants are 
responding the way that they do to their DTC PGT results. These results can help to 
support DTC PGT participants in decision-making by offering a better understanding 
about what drives their decisions. These findings also suggest that DTC PGT results are 
being used when making decisions that are important including, financial and advance 
planning decisions. The link between perceptions of results and self and these outcomes 
is important in further describing the context of decision-making in genomics and across 
age groups. 
 Keywords: Protection Motivation Theory, Direct-to-Consumer Personal Genetic 
Testing, Genetics, Advance Planning, Genomics  
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Using Age and Protection Motivation Theory to Explore Personal Genomic Testing 
Result Utilization 
 
Introduction 
As genetic information has become a larger part of the health landscape, there 
have been numerous policy and guideline changes that are intended to address concerns 
about privacy and discrimination related to genetic findings (eg. Genetic Information 
Nondiscrimination Act 2008) (Green, Lautenbach, & McGuire, 2015). Direct-to-
consumer personal genomic testing (DTC PGT) carries with it a variety of similar and 
also unique concerns when compared with clinical genetic testing. Direct-to-consumer 
personal genomic testing services do not provide individualized genetic counseling to 
accompany their results, and while the testing services do offer education related to 
testing and results, the service model leaves open the possibility of misinterpretation on 
the part of the result recipients. There have been several studies to emerge from the 
Impact of Personal Genomics (PGen) data that indicate differences in various aspects of 
consumer understanding, knowledge, and comfort with the genetic information (Carere et 
al., 2014; Carere, VanderWeele, et al., 2015; Ostergren et al., 2015). Understanding the 
way that genomic testing results may lead to changes in health behaviors is an important 
part of evaluating the full influence of genomic level information (Christensen et al., 
2015; Zick et al., 2005). Furthermore, understanding how consumers’ perceptions related 
to genomics may influence the actions they take with their genomic information may 
assist healthcare providers, policy makers, and scientists to better understand and support 
individuals who engage in DTC PGT (Kaufman, Bollinger, Dvoskin, & Scott, 2012; 
McBride et al., 2009; McBride, Wade, & Kaphingst, 2010). Previous studies have 
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examined the influence of genetic testing on individuals’ purchasing of insurance or 
management decisions and have reported mixed findings (Armstrong et al., 2003; Zick, 
Smith, Mayer, & Botkin, 2000; Zick et al., 2005). Those previous studies did not, 
however, consider the perceptions or the ages of the participants as indicators of these 
behaviors, nor did they study DTC PGT. This article evaluates differences in the DTC 
PGT result utilization behaviors as they differ among different age groups (19-39, 40-59, 
and 60+). It also explores the use of the Protection Motivation Theory (PMT) (Maddux & 
Rogers, 1983; Rogers 1983) as a way to explain the result utilization behaviors of DTC 
PGT customers.  
Protection Motivation Theory 
The PMT, in its revised version, features three main concepts: threat appraisal, 
coping appraisal, and protection motivation (Floyd, Prentice-Dunn, & Rogers, 2000; 
Maddox & Rogers, 1983; Norman, Boer, & Seydel, 2005; Rogers, 1983). Threat 
appraisal is best described as the combination of the perceived severity and the perceived 
vulnerability related to the negative outcome of concern (Rogers, 1983). This negative 
outcome could be a disease diagnosis, injury, or some other negative experience that can 
be avoided. Perceived severity is defined in terms of a person’s beliefs about the potential 
bodily harm, interpersonal threats, and intrapersonal threats that would result from the 
negative outcome. Perceived vulnerability is defined in terms of a person’s beliefs that 
they may experience the negative outcome. 
Coping appraisal is described as the combination of perceived self-efficacy and 
response efficacy related to the negative outcome of concern (Maddox & Rogers, 1983; 
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Rogers, 1983).  Response efficacy is defined as a person’s beliefs related to the 
effectiveness of coping responses. Self-efficacy is defined as a person’s beliefs about 
their ability to perform or not perform a behavior (e.g., a recommended response to the 
negative outcome of concern).  
Protection motivation is best described as the intent to adopt a recommended 
course of action or engage in a protective behavior to limit the likelihood of experiencing 
the negative outcome (Maddux & Rogers, 1983; Rogers, 1975, 1983).  The PMT is based 
on the assumption that there is a positive linear relationship among: severity of the threat, 
vulnerability to the threat, the ability to cope with the threat, and that engaging in the 
behavior of concern will decrease risks of the negative outcome (Rogers, 1983). For the 
purposes of this study, protection motivation is defined as engaging in disclosure of 
results or making changes in insurance, retirement or financial plans, or advance 
planning. 
Protection Motivation Theory and Genetics 
Protection motivation theory has been applied to a variety of studies, several of 
which have genetic relevance either directly with genetic testing, genetic information, or 
by featuring some aspect of family inheritance of diseases (Azzarello, Dessureault, & 
Jacobsen, 2006; Fisher, Bonner, Biankin, & Juraskova, 2012; Helmes 2002; Ralph et al., 
2014; Vadaparampil et al. 2004; Wright, French, Weinman, & Marteau, 2006).  Three 
distinct areas of behaviors that have been studied using the PMT with relevance to this 
study include: screening and preventive behaviors, use of genetic testing information to 
make health changes, and engagement in genetic testing. 
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In the area of screening and preventive behaviors, self-efficacy and perceived risk 
were found to be significant contributors to making changes in preventative health 
behaviors related to melanoma. (Azzarello, Dessureault, & Jacobsen, 2006). In a 
population of first-degree relatives of men with prostate cancer, self-efficacy, income and 
age were found to be contributors to making changes (Vadaparampil et al. 2004). These 
findings were consistent with the results of other research in health-protective behaviors. 
In examining the influence of genetic risk on smoking, self-efficacy was shown to have a 
significant effect on intentions to quit smoking (Wright, French, Weinman, & Marteau, 
2006). Among smokers, knowledge of increased genetic risk for lung cancer is associated 
with greater intentions to engage in smoking cessation activities when compared with 
those without any genetic risk knowledge. Protection Motivation Theory has also been 
applied to the preference for selective estrogen reuptake modulators (SERM) among 
women with an increased genetic risk of breast cancer. Ralph and associates (2014) 
evaluated the relationships among PMT concepts and intentions to engage in SERM 
treatment identifying perceived vulnerability, perceived severity, and response efficacy as 
each making a significant unique contribution to the explained variance.  
Helmes (2002) assessed the PMT’s components for predictive applications in 
understanding womens’ motivations to engage in genetic testing. The study did not fully 
support the use of the PMT as a predictive framework for genetic testing motivation 
assessment; however, there was a clear association with perceived risk and an increased 
likelihood to engage in testing.  Fisher, Bonner, Biankin, and Juraskova (2012) evaluated 
the application of PMT constructs as possible predictors of whole genome sequencing 
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(WGS) screening intentions; finding that response efficacy, response costs, and self-
efficacy each made a significant unique contribution to explained variance in the model.   
The PMT has been applied to a variety of genetic and genomic-related behaviors, 
but there is limited assessment of PMT’s applicability to DTC PGT, specifically the 
disclosure of DTC PGT results or utilization of the DTC PGT results to make changes in 
insurance, retirement, and advance planning behaviors. These areas are not currently 
addressed in the literature. This study explores the application of the PMT to genetic 
information disclosure and utilization behaviors among three age groups (19-39, 40-59, 
60+).  Our aim for this article is to explore the applicability of the PMT to the utilization 
of DTC PGT results, and to describe age group differences in use of the DTC PGT 
results.  
Design and Methods 
Sample 
 The PGen study was approved by the University of Michigan School of Public 
Health Institutional Review Board and the Partners Human Research Committee. Each 
study participant completed an electronic informed consent prior to study enrollment.  
The specific details of design and data collection for the PGen study have been reported 
previously (Carere et al., 2014; Lehmann et al., 2012). 
The sample was recruited between March and July 2012 from among new direct-
to-consumer genomic testing customers of the 23andMe and Pathway Genomics services. 
The study consisted of three online surveys that were administered by Survey Sciences 
Group (Ann Arbor, MI).  These surveys included a baseline survey that was administered 
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following the participant’s submission of a sample but prior to receipt of DTC PGT 
results, the two follow-up surveys were administered at two to three weeks and six-
months after receipt of the DTC PGT results. 
Table 4.1 
Demographic and Socioeconomic Information by Group (%) 
 19-39 Years 40-59 Years 60+ Years Overall 
Number 
Mean Age (years) 
Female  
Relationship status 
   Married/Partnered 
Have Biological Children 
Racea 
   American Indian/Native 
Alaskan 
   Asian 
   Black or African American 
   Hawaiian or Pacific Islander 
   White 
   Other Race 
Highest Level of Education 
   Less Than College 
   College Degree 
   Some Graduate School 
   Doctoral Equivalent 
Current Employment Status 
   Employed 
   Retired 
   Unemployed 
   Student 
Household Income Past 12 
Months <$100,000 
350 
  30.22 
56.9 
 
58.6 
18.9 
 
 3.1 
 9.7 
 3.7 
 1.4 
86.6 
 7.4 
 
17.2 
37.1 
35.1 
10.5 
 
81.2 
    .6 
12.6 
20.3 
 
58.9 
314 
  49.51 
64.1 
 
71.5 
60.6 
 
  1.9 
  2.2 
  3.8 
    .3 
92.4 
  4.8 
 
20.7 
31.1 
34.2 
14.0 
 
78.4 
11.1 
16.5 
  1.6 
 
48.4 
223 
  66.92 
56.1 
 
75.8 
78.5 
 
  3.6 
     .0 
   1.3 
    .4 
95.5 
  3.1 
 
25.1 
17.9 
40.0 
17.0 
 
39.0 
63.2 
  6.3 
    .0 
 
58.4 
888 
  46.28 
59.2 
 
67.4 
48.6 
 
  2.8 
  4.6 
  3.2 
    .8 
90.9 
  5.4 
 
20.4 
30.2 
36.0 
13.5 
 
69.6 
20.0 
12.4 
  8.6 
 
55.9 
Note: aSome participants indicated more than one race thus the totals exceed 100%. 
The PGen study included a total of 1,464 participants who engaged in DTC PGT. 
The sample used for this study consisted of 887, of those participants who completed the 
baseline, two to three week follow-up, and six month follow-up surveys.  Table 4.1 offers 
descriptive demographic statistics for the sample included in this analysis. 
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Measures of Perception Motivation Theory Concepts 
Perceived severity.  The measure of perceived severity is an 11-item instrument 
with a four-option, Likert-type scale with high reliability (α=.82) and robust construct 
validity (Chung et al., 2009). The scale gathers information regarding the respondents’ 
beliefs about the severity of their personal genomic testing results. These questions are 
included in the six-month follow-up questionnaire, a higher score on this scale indicates a 
higher perceived severity of the DTC PGT results. 
Perceived vulnerability.  The measure of perceived vulnerability is composed of 
nine items with a five option Likert-type scale that gathers information about 
respondents’ perceived risk of having a genetic-linked disease. These items do not relate 
to the actual results from the testing company and are solely based on the respondents’ 
beliefs about their own vulnerability to genetic disease. These questions are included in 
the six month follow-up questionnaire. A higher value indicates a higher perception of 
vulnerability to having a genetic-linked disease. 
Response efficacy. A five option Likert-type single item is used to measure 
response efficacy in respondents (Wade et al., 2012). The item is included in the six 
month follow-up questionnaire. A higher score on this item indicates a stronger belief 
that the DTC PGT results would be helpful in improving health or avoiding illness. 
Self-efficacy. The measurement for self-efficacy in respondents is a five item 
seven point Likert-type scale (Parrott, Silk, & Condit, 2003).  The scale has a high 
reliability (α=.86) (McBride et al., 2009). This scale is included in the six-month follow-
up questionnaire. Those respondents with a higher score on this scale believe that they 
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are more able to accurately engage with their genomic results and understand the results’ 
meanings on their own. 
Post Result Receipt Behaviors. The four outcome variables: 1) discussing DTC 
PGT results with someone else, 2) making a change in their insurance coverage in 
response to the DTC PGT results, 3) making a change in their retirement or financial 
plans in response to DTC PGT results, and 4) making a change in their advance planning 
as a response to their DTC PGT results are all single items. They are asked using yes or 
no answer choices on the six month follow up survey.   
Statistical Analysis 
Descriptive statistics were calculated for each of the analyzed items and 
contingency tables were constructed for each of the four post result receipt behaviors by 
each of the PMT concepts.  Due to low cell counts in all of the contingency tables chi-
square analyses were inappropriate. All analyses were run using IBM SPSS Statistics 
23.0. 
Results 
Descriptive Statistics 
 The self-reported percentages of use of the PGT results are displayed in Table 4.2 
along with the PMT conceptual measure averages included in the analysis.   
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Table 4.2 
Personal Genomic Testing Result Usage and Protection Motivation Theory Concept 
Descriptive Statistics by Age Group 
 19-39 years 40-59 years 60+ years Overall 
Intended to discuss resultsa     96.0 (336)  94.0 (296) 97.8 (218) 95.7 (850) 
Discussed resultsa     96.6 (338)  93.0 (293) 94.6 (211) 94.8 (842) 
Changed insurance coveragea      0.3 (1)    0.3 (1)   1.3 (3)   0.6 (5) 
Changed financial/retirementa      0.6 (2)    2.2 (7)   4.5 (10)   2.1 (19) 
Changed advance planninga      1.1 (4)    2.2 (7)   8.1 (18)   3.3 (29) 
Perceived Severity Scaleb      1.85 (0.37)   1.91 (0.41)   1.86 (0.40)   1.88 (0.39) 
Perceived Vulnerability Scaleb    22.67 (5.17) 23.56 (5.21) 23.44 (6.72) 23.18 (5.62) 
Response Efficacyb      3.23 (1.05)   3.42 (1.09)   3.22 (1.13)   3.30 (1.09) 
Genetic Self-Efficacyb      5.63 (1.10)   5.59 (1.11)   5.35 (1.05)   5.55 (1.09) 
Note. aItem expressed in percent (n). bItem expressed in mean (SD). 
 The distributions of the participant ratings for the four concepts of the PMT are 
depicted in the contingency tables organized by each of the four post result receipt 
behaviors among each of the age groups (Tables 4.3-4.6).   
Table 4.3  
Protection Motivation Theory Concept Ratings Among Age Groups by Sharing Personal 
Genomic Testing Results 
Response Efficacy 
 
1 2 3 4 5 
1
9
-3
9
  No 1 (8.3%) 3 (25.0%) 3 (25.0%) 5 (41.7%) 0 (0.0%) 
Yes 23 (6.8%) 56 (16.6%) 104 (30.8%) 126 (37.3%) 29 (8.6%) 
Total 24 (6.9%) 59 (16.9%) 107 (30.6%) 131 (37.4%) 29 (8.3%) 
4
0
-5
9
  No 2 (9.1%) 4 (18.2%) 9 (40.9%) 7 (31.8%) 0 (0.0%) 
Yes 19 (6.5%) 33 (11.3%) 85 (29.0%) 107 (36.5%) 49 (16.7%) 
Total 21 (6.7%) 37 (11.7%) 94 (29.8%) 114 (36.2%) 49 (15.6%) 
6
0
+
  
No 3 (25.0%) 3 (25.0%) 5 (41.7%) 1 (8.3%) 0 (0.0%) 
Yes 23 (10.9%) 20 (9.5%) 68 (32.2%) 78 (37.0%) 22 (10.4%) 
Total 26 (11.7%) 23 (10.3%) 73 (32.7%) 79 (35.4%) 22 (9.9%) 
T
o
ta
l No 6 (13.0%) 10 (21.7%) 17 (37.0%) 13 (28.3%) 0 (0.0%) 
Yes 65 (7.7%) 109 (12.9%) 257 (30.5%) 311 (36.9%) 100 (11.9%) 
Total 71 (8.0%) 119 (13.4%) 274 (30.9%) 324 (36.5%) 100 (11.3%) 
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Table 4.3 continued 
Protection Motivation Theory Concept Ratings Among Age Groups by Sharing Personal 
Genomic Testing Results 
Self-Efficacy Rating 
 
1 2 3 4 5 
1
9
-3
9
  No 0 (0.0%) 0 (0.0%) 1 (8.3%) 6 (50.0%) 5 (41.7%) 
Yes 4 (1.2%) 8 (2.4%) 32 (9.5%) 97 (28.7%) 197 (58.3%) 
Total 4 (1.1%) 8 (2.3%) 33 (9.4%) 103 (29.4%) 202 (57.7%) 
4
0
-5
9
  No 1 (4.5%) 2 (9.1%) 2 (9.1%) 8 (36.4%) 9 (40.9%) 
Yes 5 (1.7%) 3 (1.0%) 20 (6.8%) 109 (37.2%) 156 (53.2%) 
Total 6 (1.9%) 5 (1.6%) 22 (7.0%) 117 (37.1%) 165 (52.4%) 
6
0
+
  
No 1 (8.3%) 1 (8.3%) 4 (33.3%) 3 (25.0%) 3 (25.0%) 
Yes 3 (1.4%) 3 (1.4%) 23 (10.9%) 88 (41.7%) 94 (44.5%) 
Total 4 (1.8%) 4 (1.8%) 27 (12.1%) 91 (40.8%) 97 (43.5%) 
T
o
ta
l No 2 (4.3%) 3 (6.5%) 7 (15.2%) 17 (37.0%) 17 (37.0%) 
Yes 12 (1.4%) 14 (1.7%) 75 (8.9%) 294 (34.9%) 447 (53.1%) 
Total 14 (1.6%) 17 (1.9%) 82 (9.2%) 311 (35.0%) 464 (52.3%) 
Perceived Severity Rating 
 
1 2 3 
1
9
-3
9
  No 5 (41.7%) 6 (50.0%) 1 (8.3%) 
Yes 50 (14.8%) 266 (78.7%) 22 (6.5%) 
Total 55 (15.7%) 272 (77.7%) 23 (6.6%) 
4
0
-5
9
  No 4 (18.2%) 14 (63.6%) 4 (18.2%) 
Yes 47 (16.0%) 222 (75.8%) 24 (8.2%) 
Total 51 (16.2%) 236 (74.9%) 28 (8.9%) 
6
0
+
  
No 3 (25.0%) 7 (58.3%) 2 (16.7%) 
Yes 36 (17.1%) 158 (74.9%) 17 (8.1%) 
Total 39 (17.5%) 165 (74.0%) 19 (8.5%) 
T
o
ta
l No 12 (26.1%) 27 (58.7%) 7 (15.2%) 
Yes 133 (15.8%) 646 (76.7%) 63 (7.5%) 
Total 145 (16.3%) 673 (75.8%) 70 (7.9%) 
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Table 4.3 continued 
Protection Motivation Theory Concept Ratings Among Age Groups by Sharing Personal 
Genomic Testing Results 
Perceived Vulnerability Rating 
 
1 2 3 4 5 
1
9
-3
9
 No 0 (0.0%) 3 (25.0%) 7 (58.3%) 2(16.7%) 0 (0.0%) 
Yes 5 (1.5%) 30 (8.9%) 165 (48.8%) 128 (37.9%) 10 (3.0%) 
Total 5 (1.4%) 33 (9.4%) 172 (49.1%) 130 (37.1%) 10 (2.9%) 
4
0
-5
9
 No 0 (0.0%) 3 (13.6%) 11 (50.0%) 6 (7.3%) 2 (9.1%) 
Yes 2 (.7%) 26 (8.9%) 133 (45.5%) 122 (41.8%) 9 (3.1%) 
Total 2 (.6%) 29 (9.2%) 144 (45.9%) 128 (40.8%) 11 (3.5%) 
6
0
+
 No 0 (0.0%)  3 (25.0%) 6 (50.0%) 2 (16.7%) 1 (8.3%) 
Yes 0 (0.0%)  30 (14.2%) 94 (44.5%) 70 (33.2%) 17 (8.1%) 
Total 0 (0.0%)  33 (14.8%) 100 (44.8%) 72 (32.3%) 18 (8.1%) 
T
o
ta
l No 0 (0.0%) 9 (19.6%) 24 (52.2%) 10 (21.7%) 3 (6.5%) 
Yes 7 (.8%) 86 (10.2%) 392 (46.6%) 320 (38.0%) 36 (4.3%) 
Total 7 (.8%) 95 (10.7%) 416 (46.9%) 330 (37.2%) 39 (4.4%) 
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Table 4.4  
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes 
to Health Insurance  
Response Efficacy 
 
1 2 3 4 5 
1
9
-3
9
 No 24 (6.9%) 59 (16.9%) 106 (30.4%) 131 (37.5%) 29 (8.3%) 
Yes 0 (0.0%) 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 
Total 24 (6.9%) 59 (16.9%) 107 (30.6%) 131 (37.4%) 29 (8.3%) 
4
0
-5
9
 No 21 (6.7%) 37 (11.8%) 94 (29.9%) 114 (36.3%) 48 (15.3%) 
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (100.0%) 
Total 21 (6.7%) 37 (11.7%) 94 (29.8%) 114 (36.2%) 49 (15.6%) 
6
0
+
 No 26 (11.8%) 22 (10.0%) 73 (33.2%) 79 (35.9%) 20 (9.1%) 
Yes 0 (0.0%) 1 (33.3%) 0 (0.0%) 0 (0.0%) 2 (66.7%) 
Total 26 (11.7%) 23 (10.3%) 73 (32.7%) 79 (35.4%) 22 (9.9%) 
T
o
ta
l No 71 (8.0%) 118 (13.4%) 273 (30.9%) 324 (36.7%) 97 (11.0%) 
Yes 0 (0.0%) 1 (20.0%) 1 (20.0%) 0 (0.0%) 3 (60.0%) 
Total 71 (8.0%) 119 (13.4%) 274 (30.9%) 324 (36.5%) 100 (11.3%) 
Self-Efficacy Rating 
 
1 2 3 4 5 
1
9
-3
9
 No 4 (1.1%) 8 (2.3%) 33 (9.5%) 102 (29.2%) 202 (57.9%) 
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (100.0%) 0 (0.0%) 
Total 4 (1.1%) 8 (2.3%) 33 (9.4%) 103 (29.4%) 202 (57.7%) 
4
0
-5
9
 No 6 (1.9%) 5 (1.6%) 22 (7.0%) 116 (36.9%) 165 (52.5%) 
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (100.0%) 0 (0.0%) 
Total 6 (1.9%) 5 (1.6%) 22 (7.0%) 117 (37.1%) 165 (52.4%) 
6
0
+
 No 4 (1.8%) 4 (1.8%) 26 (11.8%) 91 (41.4%) 95 (43.2%) 
Yes 0 (0.0%) 0 (0.0%) 1 (33.3%) 0 (0.0%) 2 (66.7%) 
Total 4 (1.8%) 4 (1.8%) 27 (12.1%) 91 (40.8%) 97 (43.5%) 
T
o
ta
l No 14 (1.6%) 17 (1.9%) 81 (9.2%) 309 (35.0%) 462 (52.3%) 
Yes 0 (0.0%) 0 (0.0%) 1 (20.0%) 2 (40.0%) 2 (40.0%) 
Total 14 (1.6%) 17 (1.9%) 82 (9.2%) 311 (35.0%) 464 (52.3%) 
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Table 4.4 continued 
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes 
to Health Insurance 
Perceived Severity Rating 
 
1 2 3 
1
9
-3
9
 No 55 (15.8%) 271 (77.7%) 23 (6.6%) 
Yes 0 (0.0%) 1 (100.0%) 0 (0.0%) 
Total 55 (15.7%) 272 (77.7%) 23 (6.6% 
4
0
-5
9
 No 51 (16.2%) 235 (74.8%) 28 (8.9%) 
Yes 0 (0.0%) 1 (100.0%) 0 (0.0%) 
Total 51 (16.2%) 236 (74.9%) 28 (8.9%) 
6
0
+
 No 39 (17.7%) 163 (74.1%) 18 (8.2%) 
Yes 0 (0.0%) 2 (66.7%) 1 (33.3%) 
Total 39 (17.5%) 165 (74.0% 19 (8.5%) 
T
o
ta
l No 145 (16.4%) 669 (75.8%) 69 (7.8%) 
Yes 0 (0.0%) 4 (80.0%) 1 (20.0%) 
Total 145 (16.3%) 673 (75.8%) 70 (7.9%) 
Perceived Vulnerability Rating 
 
1 2 3 4 5 
1
9
-3
9
 No 5 (1.4%) 33 (9.5%) 171 (49.0%) 130 (37.2%) 10 (2.9%) 
Yes 0 (0.0%) 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 
Total 5 (1.4%) 33 (9.4%) 172 (49.1%) 130 (37.1%) 10 (2.9%) 
4
0
-5
9
 No 2 (.6%) 29 (9.3%) 143 (45.7%) 128 (40.9%) 11 (3.5%) 
Yes 0 (0.0%) 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 
Total 2 (.6%) 29 (9.2%) 144 (45.9%) 128 (40.8%) 11 (3.5%) 
6
0
+
 No 0 (0.0%) 32 (14.5%) 99 (45.0%) 71 (32.3%) 18 (8.2%) 
Yes 0 (0.0%) 1 (33.3%) 1 (33.3%) 1 (33.3%) 0 (0.0%) 
Total 0 (0.0%) 33 (14.8%) 100 (44.8%) 72 (32.3%) 18 (8.1%) 
T
o
ta
l No 7 (.8%) 94 (10.7%) 413 (46.8%) 329 (37.3%) 39 (4.4%) 
Yes 0 (0.0%) 1 (20.0%) 3 (60.0%) 1 (20.0%) 0 (0.0%) 
Total 7 (.8%) 95 (10.7%) 416 (46.9%) 330 (37.2%) 39 (4.4%) 
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Table 4.5 
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes 
to Retirement/Finances 
Response Efficacy 
 
1 2 3 4 5 
1
9
-3
9
  No 24 (6.9%) 59 (17.0%) 105 (30.2%) 131 (37.6%) 29 (8.3%) 
Yes 0 (0.0%) 0 (0.0%) 2 (100.0%) 0 (0.0%) 0 (0.0%) 
Total 24 (6.9%) 59 (16.9%) 107 (30.6%) 131 (37.4%) 29 (8.3%) 
4
0
-5
9
  No 21 (6.8%) 36 (11.7%) 92 (29.9%) 110 (35.7%) 49 (15.9%) 
Yes 0 (0.0%) 1 (14.3%) 2 (28.6%) 4 (57.1%) 0 (0.0%) 
Total 21 (6.7%) 37 (11.7%) 94 (29.8%) 114 (36.2%) 49 (15.6%) 
6
0
+
  
No 26 (12.2%) 23 (10.8%) 72 (33.8%) 71 (33.3%) 21 (9.9%) 
Yes 0 (0.0%) 0 (0.0%) 1 (10.0%) 8 (80.0%) 1 (10.0%) 
Total 26 (11.7%) 23 (10.3%) 73 (32.7%) 79 (35.4%) 22 (9.9%) 
T
o
ta
l No 71 (8.2%) 118 (13.6%) 269 (31.0%) 312 (35.9%) 99 (11.4%) 
Yes 0 (0.0%) 1 (5.3%) 5 (26.3%) 12 (63.2%) 1 (5.3%) 
Total 71 (8.0%) 119 (13.4%) 274 (30.9%) 324 (36.5%) 100 (11.3%) 
Self-Efficacy Rating 
 
1 2 3 4 5 
1
9
-3
9
  No 4 (1.1%) 8 (2.3%) 32 (9.2%) 102 (29.3%) 202 (58.0%) 
Yes 0 (0.0%) 0 (0.0%) 1 (50.0%) 1 (50.0%) 0 (0.0%) 
Total 4 (1.1%) 8 (2.3%) 33 (9.4%) 103 (29.4%) 202 (57.7%) 
4
0
-5
9
  No 6 (1.9%) 4 (1.3%) 22 (7.1%) 116 (37.7%) 160 (51.9%) 
Yes 0 (0.0%) 1 (14.3%) 0 (0.0%) 1 (14.3%) 5 (71.4%) 
Total 6 (1.9%) 5 (1.6%) 22 (7.0%) 117 (37.1%) 165 (52.4%) 
6
0
+
  
No 4 (1.9%) 4 (1.9%) 27 (12.7%) 86 (40.4%) 92 (43.2%) 
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (50.0%) 5 (50.0%) 
Total 4 (1.8%) 4 (1.8%) 27 (12.1%) 91 (40.8%) 97 (43.5%) 
T
o
ta
l No 14 (1.6%) 16 (1.8%) 81 (9.3%) 304 (35.0%) 454 (52.2%) 
Yes 0 (0.0%) 1 (5.3%) 1 (5.3%) 7 (36.8%) 10 (52.6%) 
Total 14 (1.6%) 17 (1.9%) 82 (9.2%) 311 (35.0%) 464 (52.3%) 
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Table 4.5 continued 
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes 
to Retirement/Finances 
Perceived Severity Rating 
 
1 2 3 
1
9
-3
9
  No 55 (15.8%) 270 (77.6%) 23 (6.6%) 
Yes 0 (0.0%) 2 (100.0%) 0 (0.0%) 
Total 55 (15.7%) 272 (77.7%) 23 (6.6%) 
4
0
-5
9
  No 50 (16.2%) 232 (75.3%) 26 (8.4%) 
Yes 1 (14.3%) 4 (57.1%) 2 (28.6%) 
Total 51 (16.2%) 236 (74.9%) 28 (8.9%) 
6
0
+
  
No 37 (17.4%) 158 (74.2%) 18 (8.5%) 
Yes 2 (20.0%) 7 (70.0%) 1 (10.0%) 
Total 39 (17.5%) 165 (74.0%) 19 (8.5%) 
T
o
ta
l No 142 (16.3%) 660 (75.9%) 67 (7.7%) 
Yes 3 (15.8%) 13 (68.4%) 3 (15.8%) 
Total 145 (16.3%) 673 (75.8%) 70 (7.9%) 
Perceived Vulnerability Rating 
 
1 2 3 4 5 
1
9
-3
9
  No 5 (1.4%) 33 (9.5%) 171 (49.1%) 129 (37.1%) 10 (2.9%) 
Yes 0 (0.0%) 0 (0.0%) 1 (50.0%) 1 (50.0%) 0 (0.0%) 
Total 5 (1.4%) 33 (9.4%) 172 (49.1%) 130 (37.1%) 10 (2.9%) 
4
0
-5
9
  No 2 (.7%) 28 (9.1%) 144 (46.9%) 124 (40.4%) 9 (2.9%) 
Yes 0 (0.0%) 1 (14.3%) 0 (0.0%) 4 (57.1%) 2 (28.6%) 
Total 2 (.6%) 29 (9.2%) 144 (45.9%) 128 (40.8%) 11 (3.5%) 
6
0
+
  
No 0 (0.0%) 31 (14.6%) 96 (45.1%) 71 (33.3%) 15 (7.0%) 
Yes 0 (0.0%) 2 (20.0%) 4 (40.0%) 1 (10.0%) 3 (30.0%) 
Total 0 (0.0%) 33 (14.8%) 100 (44.8%) 72 (32.3%) 18 (8.1%) 
T
o
ta
l No 7 (.8%) 92 (10.6%) 411 (47.4%) 324 (37.3%) 34 (3.9%) 
Yes 0 (0.0%) 3 (15.8%) 5 (26.3%) 6 (31.6%) 5 (26.3%) 
Total 7 (.8%) 95 (10.7%) 416 (46.9%) 330 (37.2%) 39 (4.4%) 
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Table 4.6 
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes 
to Advance Planning 
Response Efficacy 
 
1 2 3 4 5 
1
9
-3
9
  No 24 (6.9%) 59 (17.1%) 107 (30.9%) 129 (37.3%) 27 (7.8%) 
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (50.0%) 2 (50.0%) 
Total 24 (6.9%) 59 (16.9%) 107 (30.6%) 131 (37.4%) 29 (8.3%) 
4
0
-5
9
  No 21(6.8%) 37 (12.0%) 94 (30.5%) 111 (36.0%) 45 (14.6%) 
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (42.9%) 4 (57.1%) 
Total 21 (6.7%) 37 (11.7%) 94 (29.8%) 114 (36.2%) 49 (15.6%) 
6
0
+
  
No 26 (12.7%) 22 (10.7%) 69 (33.7%) 68 (33.2%) 20 (9.8%) 
Yes 0 (0.0%) 1 (5.6%) 4 (22.2%) 11 (61.1%) 2 (11.1%) 
Total 26 (11.7%) 23 (10.3%) 73 (32.7%) 79 (35.4%) 22 (9.9%) 
T
o
ta
l No 71 (8.3%) 118 (13.7%) 270 (31.4%) 308 (35.9%) 92 (10.7%) 
Yes 0 (0.0%) 1 (3.4%) 4 (13.8%) 16 (55.2%) 8 (27.6%) 
Total 71 (8.0%) 119 (13.4%) 274 (30.9%) 324 (36.5%) 100 (11.3%) 
Self-Efficacy Rating 
 
1 2 3 4 5 
1
9
-3
9
  No 4 (1.2%) 8 (2.3%) 33 (9.5%) 101 (29.2%) 200 (57.8%) 
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (50.0%) 2 (50.0%) 
Total 4 (1.1%) 8 (2.3%) 33 (9.4%) 103 (29.4%) 202 (57.7%) 
4
0
-5
9
  No 6 (1.9%) 5 (1.6%) 22 (7.1%) 115 (37.3%) 160 (51.9%) 
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (28.6%) 5 (71.4%) 
Total 6 (1.9%) 5 (1.6%) 22 (7.0%) 117 (37.1%) 165 (52.4%) 
6
0
+
  
No 4 (2.0%) 4 (2.0%) 23 (11.2%) 84 (41.0%) 90 (43.9%) 
Yes 0 (0.0%) 0 (0.0%) 4 (22.2%) 7 (38.9%) 7 (38.9%) 
Total 4 (1.8%) 4 (1.8%) 27 (12.1%) 91 (40.8%) 97 (43.5%) 
T
o
ta
l No 14 (1.6%) 17 (2.0%) 78 (9.1%) 300 (34.9%) 450 (52.4%) 
Yes 0 (0.0%) 0 (0.0%) 4 (13.8%) 11 (37.9%) 14 (48.3%) 
Total 14 (1.6%) 17 (1.9%) 82 (9.2%) 311 (35.0%) 464 (52.3%) 
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Table 4.6 continued 
Protection Motivation Theory Concept Ratings Among Age Groups by Making Changes 
to Advance Planning 
Perceived Severity Rating 
 
1 2 3 
1
9
-3
9
 No 55 (15.9%) 268 (77.5%) 23 (6.6%) 
Yes 0 (0.0%) 4 (100.0%) 0 (0.0%) 
Total 55(15.7%) 272 (77.7%) 23 (6.6%) 
4
0
-5
9
 No 50 (16.2%) 234 (76.0%)  24 (7.8%) 
Yes 1 (14.3%) 2 (28.6%) 4 (57.1%) 
Total 51 (16.2%) 236 (74.9%) 28 (8.9%) 
6
0
+
 No 37 (18.0%) 151 (73.7%) 17 (8.3%) 
Yes 2 (11.1%) 14 (77.8%) 2 (11.1%) 
Total 39 (17.5%) 165 (74.0%) 19 (8.5%) 
T
o
ta
l No 142 (16.5%) 653 (76.0%) 64 (7.5%) 
Yes 3 (10.3%) 20 (69.0%) 6 (20.7%) 
Total 145 (16.3%) 673 (75.8%) 70 (7.9%) 
Perceived Vulnerability Rating 
 
1 2 3 4 5 
1
9
-3
9
  No 5 (1.4%) 32 (9.2%) 171 (49.4%) 128 (37.0%) 10 (2.9%) 
Yes 0 (0.0%) 1 (25.0%) 1 (25.0%) 2 (50.0%) 0 (0.0%) 
Total 5 (1.4%) 33 (9.4%) 172 (49.1%) 130 (37.1%) 10 (2.9%) 
4
0
-5
9
  No 2 (.7%) 28 (9.1%) 142 (46.3%) 125 (40.7%) 10 (3.3%) 
Yes 0 (0.0%) 1 (14.3%) 2 (28.6%) 3 (42.9%) 1 (14.3%) 
Total 2 (.6%) 29 (9.2%) 144 (45.9%) 128 (40.8%) 11 (3.5%) 
6
0
+
  
No 0 (0.0%) 33 (16.1%) 91 (44.4%) 68 (33.2%) 13 (6.3%) 
Yes 0 (0.0%) 0 (0.0%) 9 (50.0%) 4 (22.2%) 5 (27.8%) 
Total 0 (0.0%) 33 (14.8%) 100 (44.8%) 72 (32.3%) 18 (8.1%) 
T
o
ta
l No 7 (.8%) 93 (10.8%) 404 (47.1%) 321 (37.4%) 33 (3.8%) 
Yes 0 (0.0%) 2 (6.9%) 12 (41.4%) 9 (31.0%) 6 (20.7%) 
Total 7 (.8%) 95 (10.7%) 416 (46.9%) 330 (37.2%) 39 (4.4%) 
 
Discussion 
 The analyses conducted sought to better understand several interpersonal and 
economic behaviors of people following the receipt of DTC PGT results. We were able to 
use age groups and the concepts of the PMT to analyze the respondents’ decisions to 
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disclose their testing results to others, change health insurance, change financial and 
retirement plans, and change advance planning behaviors. The small size of those 
participants who engaged in the behaviors of interest limited the use of statistical analysis 
methods, and thus there are no statements of statistical significance among the 
contingency tables (Tables 4.3-4.6).  Analyses of these numbers instead focuses on the 
ratings of the four PMT concept measures as they differ among the age groups and the 
differences between those who did and did not engage in the behavior. 
These measures of the PMT concepts show some of the trends that are associated 
with taking or not taking the actions of interest and are important for the future of DTC 
PGT in the context of society and healthcare.  As genomic level knowledge permeates 
society, more people will be armed with a large amount of information that may lead 
them to engage in any of these actions.  Understanding these trends helps to better 
understand the influence that participant perceptions of self-efficacy, response efficacy, 
risk, and vulnerability have over these four results utilization behaviors.   
In examining the sharing of DTC PGT results with another person, those who did 
share tended to have higher self-efficacy and response efficacy ratings.  A majority of 
those who shared their DTC PGT results had moderate perceived severity ratings and 
moderate to higher perceived vulnerability ratings.  When examining trends among the 
age groups the patterns of ratings among those who did share their results mirror the 
overall patterns.  Greater than 80% of those who shared had high self-efficacy ratings in 
each of the three age groups and in the overall sample.  The perceived vulnerability 
   
74 
 
ratings were higher among the 60+ group who shared their results than those who shared 
in the other two age groups. 
More people did share their results from the DTC PGT than those who did not, 
this may suggest that they are seeking out the opinions of others (eg, family members, 
healthcare providers) regarding their results.  In light of the increased perceived 
vulnerability scores, the opinions sought could range from seeking other’s views on DTC 
PGT in general to dealing with specific results and many other possible perspectives of 
the results (McBride et al., 2010). 
In examining the use of the DTC PGT results to make changes in insurance, a 
very low number of events prohibits making strong statements about these participants, 
though broadly across all age groups it is evident that moderate perceived severity and 
perceived vulnerability along with higher response efficacy and self-efficacy ratings were 
more common among those who did make changes to their insurance in response to 
receiving their DTC PGT results. 
Those who made changes to their retirement and financial plans in response to 
receiving DTC PGT results were more likely to have moderate to higher response 
efficacy ratings, higher self-efficacy ratings, moderate perceived severity, and moderate 
to higher perceived vulnerability ratings. Across the age groups these were very similar, 
though the 19-39 group members who made changes were likely to have more moderate 
self-efficacy and response efficacy results than the other two age groups. 
The overall trends of those who made changes to their advance directives are the 
same as those who made changes to retirement and financial plans.  In both cases, the 
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majority of those participants who made changes were members of the 60+ group, though 
much more in the retirement changes than any other behavior.  Those in the 60+ group 
who made changes to their retirement were more likely to have moderate to higher 
response efficacy ratings compared to the other two age groups where those who changed 
had high response efficacy ratings.  
In the application of the PMT, Rogers (1983) identifies perceived vulnerability 
and perceived severity as contributing to the fear appeal that contributes to the drive to 
make changes in behavior.  The findings related to these two significant measures in the 
four tables both support and contradict that statement. Those who had a higher perceived 
vulnerability are more likely to engage in the practice of sharing their DTC PGT 
results—the target behavior thus supporting the value of fear appeals. However, the lack 
of differentiation among those who did make changes to retirement by type of changes 
(eg. adding money, removing money, increasing deductions) makes it difficult to 
determine if the behaviors related to a moderate perceived severity are consistent with 
Rogers’ thoughts about PMT (1983). The findings of this study are similar to others in 
noting a paradox in the perceived vulnerability and perceived severity scores and their 
influence on the behaviors of interest (Cismaru & Lavack, 2007). The fear of negative 
consequences can only be examined through the lens of the participant’s evaluation of the 
severity of the consequences (Rogers, 1983). 
Age group differences in engagement in the target behaviors may be related to 
situational aspects of the age groups.   The 60+ group made up the largest portion of 
those who made changes in advance directives in response to their DTC PGT results, 
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which may speak to a perception among this age group of increased proximity of age-
related decline or later-life disease processes. This older age group may view their results 
as fatalistic and seek to be proactive in addressing the possibility of a negative outcome 
related to genetic disease. Research has shown that 60+ year olds are more likely to have 
an advance directive in place than other age groups (Rao, Anderson, Lin, Laux, 2014). 
The findings of this study indicate an early indication that the PMT may be a 
valuable tool in the evaluation of decisions made in response to DTC PGT results, an area 
that had not been previously studied using PMT. Additionally, the concepts of the PMT 
are key as they support the importance of the DTC PGT consumers’ perceptions in their 
processing the results delivered by the service they used (Kaufman et al., 2012; McBride 
et al., 2010).   
Limitations 
The PGen data set provides a robust study design with a large sample of 
participants; however, there are limitations to the use of the data in this study.  The 
sample is not as diverse as society, and is made up of mostly white, married females. 
Self-selection bias is also a concern for this data set as the respondents opted into the 
study after initiating DTC PGT. Additionally, the non-controlled design of the PGen 
study cannot support any conclusions related causal relationships. The small sample of 
events of interest is one large limitation on the analysis, and while this analysis addresses 
trends in ratings among age groups in those who did engage in the target events it does 
not offer statistical evaluations of significance because of the limited sample size. The 
findings in this article are specifically about DTC PGT participants’ behaviors, but they 
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may offer some insight into trends that may also be present in clinical genetic testing 
populations. Further examination of the PMT as a model for the evaluation and study of 
DTC PGT results utilization behaviors and determining whether these trends exist outside 
of the study sample will require further studies in more diverse populations.  
Conclusions 
 The relationships among age, the PMT concepts, and insurance, financial, 
retirement, advance directive and results disclosure behaviors of DTC PGT participants 
are multifaceted.  Evaluation of the concepts in the PMT appears to aid in better 
understanding the actions that DTC PGT consumers take in response to their results. In 
addition to the perceptions included in the PMT concepts, the influence of age group 
membership must also be acknowledged as a difference in those who engaged in 
retirement and advance planning change behaviors; further study would be valuable in 
offering a deeper assessment of these age group differences.  Also, further study will be 
valuable to evaluate the PMT concepts in genetic decision-making outside of the DTC 
PGT context.  Subsequent studies—quantitative and qualitative—are needed to help 
better understand how DTC PGT companies and healthcare providers can best support 
the educational and decision-making needs of all those who engage in DTC PGT. A 
larger study with a larger sample of DTC PGT result utilization behavior events is key in 
understanding the role of the PMT in explaining these behaviors. In addition, there is a 
need to acknowledge the policy implications that these behaviors may have, while these 
tests are not necessarily entered into the medical record, they are influencing the 
consumer behaviors of the result recipients (Kaufman et al., 2012; McBride et al, 2009, 
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2010).  Policy makers must seek to find balance in protecting commercial and consumer 
interests as they address the new frontiers of consumer-driven health services. 
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CHAPTER FIVE 
CONCLUSION 
 This dissertation set out to increase the state of understanding of the beliefs, 
knowledge, and perceptions of older adults related to genetics and genomics. Studies of 
decision-making related to engaging in genomic testing and utilization of the genomic 
testing results were conducted. In order to better describe older adults, the study 
compared the differences and similarities in measures over time and among three age 
groups, 19-39 year olds, 40-59 year olds, and 60+ year olds. The focus was on older 
adults in order to strengthen the current knowledge and add new findings to provide a 
foundation for further study to be able to move toward more individualized approaches 
informed by the similarities and differences of the age groups. 
The three manuscripts included in this dissertation approach the area of genetic 
and genomic testing and decision-making from unique angles.  The manuscripts attempt 
not only to describe the various concepts, measures, and behaviors of interest by age 
group but also to contextualize them within genetics and genomics. Combined, the 
manuscripts help to frame genetic and genomic information and decision-making across 
age groups to build on past studies in genetics, genomics, decision-making, and older 
adults.  
Overview of Manuscripts 
The first manuscript examines several concepts of behavioral economics, 
exploring the possibilities of applying the behavioral economic concepts in decision-
making support related to genomics.  Written as a general overview of the concepts for a 
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naïve audience of healthcare providers and researchers, the first manuscript provides 
specific situations where the concepts may be of value in clinical practice.  Several 
concepts of behavioral economics prove to be valuable ways to explore decision-making 
and decision-support in the area of genomics. While these concepts have value, genomic 
testing and information stimulates emotions that may move beyond the realm of 
behavioral economic perspectives. Individual contexts are an important part of the 
application of behavioral economics. This manuscript is on the leading edge of genomics 
and behavioral economics, and this area of study shows promise for future development. 
The second manuscript utilizes a secondary analysis of the Impact of Personal 
Genomics (PGen) data set to examine age group differences in knowledge, perspectives, 
and beliefs related to genetics and genomics, genetic testing and results.  The article 
examines differences among the age groups in five specific areas: genetic knowledge, 
self-rated genetic competency, beliefs about personal utility of genetics, response efficacy 
of genetics, and influencers and reasons for engaging in direct-to-consumer personal 
genomic testing (DTC PGT). This article identifies several differences over time and 
among age groups related to these measures that provide insight into the age groups and 
general trends as they change over time. One overall pattern of note is that from initial 
evaluation to the six month follow-up evaluation the mean values for self-rated genetic 
competency, personal utility of genetics, and genetic response efficacy all decreased 
significantly, which may suggest that over time and exposure to the DTC PGT results the 
participants felt less confident in themselves, the testing, and the usefulness of the results. 
Age group differences were significant among the 60+ group in genetic knowledge and 
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personal utility of genetics. These may be areas where the 60+ population may benefit 
from increased support when engaging in genetic decision-making or genetic testing in 
general. Factor analysis of 19 items that evaluated participants’ influences and motives 
for engaging in DTC PGT identified two unique factors for the overall population, 
‘Health and Future’ and ‘Curiosity and Intrigue.’ Age group membership was a 
significant contributor to variance of mean scores of the ‘Health and Future’ factor with 
the 60+ group having a significantly lower mean score than the other two age groups. 
This manuscript is written with the intent to further examine differences noted among age 
groups in previous studies on genetic knowledge, and examine any differences in the 
other areas in order to build a new and better understanding of age group differences 
related to decision-making, genetics and genomics, and testing and results. 
The third manuscript also utilizes a secondary analysis of the PGen data set as it 
explores the use of the Protection Motivation Theory (PMT) as a framework for better 
understanding reaction-behaviors of DTC PGT consumers in response to their results. 
The four specific reaction-behaviors of interest included: 1) disclosing of the DTC PGT 
results to someone else, 2) making changes to health insurance, 3) making changes to 
retirement and financial plans, and 4) making changes to advance planning.  In addition 
to the concepts of the PMT, age group membership was included in the exploration of the 
behaviors. The findings of the study support the application of the PMT to DTC PGT 
consumer behaviors. Higher levels of response efficacy and self-efficacy were noted to 
be present in those who engaged in the studied behaviors following DTC PGT result 
receipt. This manuscript offers a novel area of application of the PMT in genetics and has 
   
86 
 
the possibility to inform future study and policy as the fields of genetic testing and DTC 
PGT continue to develop. The application of the PMT to these behaviors also supports 
the use of this model in further studies of decision-making in DTC PGT and clinical 
genetic testing populations. 
Limitations and Gaps 
 Each of the three manuscripts has strengths and weaknesses. This dissertation 
includes one literature-based manuscript and two secondary data analysis-based 
manuscripts.  The literature-based manuscript must be evaluated in light of the fact that 
there is currently limited research addressing the relationship between genetics and 
behavioral economic concepts.  Genetic decision-making also has a limited research 
literature base. The aim of the manuscript is to examine both fields and explore the areas 
where overlap exists with potential as new areas for research.   
While the PGen study was well designed, provided a vast amount of information 
about the participants, and evaluated a variety of concepts, limitations still exist. The 
findings in the two data-based manuscripts in this dissertation are limited in that they rely 
heavily on data collected by other scientists among a population that is less diverse than 
the general population related to a lack of diversity in ethnicity, educational attainment, 
and income distribution. There is inherent selection bias in the self-referral design used 
via the online survey service and randomization to provide a control group to strengthen 
comparisons was not feasible. Age grouping of the data also has limitations as there are 
numerous differences among age groups that may influence participation and even 
accuracy of the survey program. Additionally, the differences among those members in 
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the 60+ age group must be acknowledged as the life changes that occur after 60 years of 
age create a greater diversity among this age group than the age grouping may suggest. It 
is also important to acknowledge the very different circumstances that may surround 
clinical genetic testing which may not be present when the participants engaged in DTC 
PGT. The underlying nature of the genetic information does, however, create a common 
thread between DTC PGT results and clinical genetic or genomic testing. 
Even with limitations, the PGen data does provide valuable initial glimpses of 
how individuals engage with decision-making and results utilization related to genetic-
level knowledge. The dissertation work does have a few gaps, since it does not provide 
direct insight into the clinical genetics area. While using behavioral economics as an 
initial point of exploration, due to the secondary analysis design, the analysis could not be 
designed to test behavioral economics concepts directly. There are also some challenges 
in the direct translation of the behavioral economics and genetics findings into practice.  
There must be decision-making support and at the same time the limitation or alleviation 
of any perceived or actual coercion in the support provided.  
 In addition, the age-related differences described in this dissertation may change 
as generations of people with more exposure to the science of genetics and genetic testing 
age. This may mean that older adults may still have differences, but the knowledge-based 
measures may vary.  Though it should be noted that as the age-knowledge difference may 
narrow, it is highly unlikely that the differences in genetic knowledge associated with age 
will be eliminated entirely as advances in genetics continue to be made. Additionally, the 
low number of events related to results utilization is a limitation in making any broad 
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generalizations to these behaviors—though it may offer important insight for the design 
of future research. 
Discussion and Recommendations  
In looking at the three manuscripts individually and as a collective work, it is 
apparent that the area of genetic decision-making is complex and still in the early stages 
of understanding. There is currently a limited foundation on which one can build a 
universal approach to making these decisions because of the unique nature of the genetic 
information that is provided through testing. The findings from these manuscripts may 
not be fully generalizable to the clinical testing experience; however, they do provide 
some insights into age group similarities and differences in trends, behaviors, and 
influences of genetic decision-making processes. Those insights may add to other 
research in the field to influence the design and implementation of clinical genetics 
studies or trials that address decision-making, decision aides and other interventions. 
There are clear differences in the older adult population, and these differences 
support the need for unique approaches especially in the area of genetics.  As suggested 
previously, the results of the second and third manuscripts have limited generalization 
potential. These findings need to be evaluated in more diverse populations and clinical 
testing situations to see if the findings are similar to those presented here.  
The PMT has been applied in various aspects of genetics, but this is the first time 
where PMT has been applied to decision-making related to the utilization and disclosure 
of DTC PGT results, and genetic test results in general (Azzarello et al., 2006; Fisher et 
al., 2012; Helmes 2002; Ralph et al., 2014; Vadaparampil et al. 2004; Wright et al., 
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2006). Additionally, the PMT constructs may be helpful in designing and testing 
decision-making tools and interventions to support the decision-making process. 
This work has implications for practice, education, and policy, as it brings new 
findings and perspectives to the study of genomics and gerontology. In the realm of 
practice, the work of this dissertation can help increase the awareness of the context of 
decision-making related to healthcare and genetics (Bayliss et al, 2014; Operskalski & 
Barbey, 2016). Understanding that while shared decision-making and other tactics are in 
existence, the individual realities of the patients who are making the decisions must also 
be taken into account. Health care practice is moving toward an even more personalized 
approach as patient satisfaction and customer service become hallmarks of the industry 
that used to coast on “doctor knows best” paternalism (Drolet & White, 2012). In this 
new approach to healthcare, professionals must be informed about the range of contextual 
factors that influence the actions and desires of patients. In addition to the concepts of the 
PMT, the application of behavioral economic approaches to supporting decision-making 
in genetics may offer a good starting place. 
As for educational implications, this work is helpful in further defining the unique 
needs of older adult populations specifically in genetic decision-making.  Healthcare 
providers and researchers need to be educated about and encouraged to understand these 
needs and differences among age groups. The ability of the PMT to be applied in 
predicting behaviors after receipt of DTC PGT results further supports a need for holistic 
approaches to patient care. Healthcare providers should be trained to engage patients and 
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understand their individual perspectives and beliefs when engaging in genetic testing 
decision-making and discussing health behavior changes. 
The growing areas of DTC PGT, clinical genetics, and genetic science in general 
continue to push the bounds of extant policy (McBride et al., 2010). While GINA and 
other policies that address genetic discrimination exist now to protect the rights of the 
individual to access the latest technologies available without fear of retribution, these 
policies will need to be revisited often in order to address new areas of concern as they 
develop (Green et al., 2015). The reactive behaviors of the DTC PGT participants are one 
example of a possible new area where policy intervention may be needed.  When policies 
are developed to address these areas, it is imperative to protect both citizen interests and 
private interests.  In the absence of a dual protection, provision of services may become 
too expensive or risky for the private entities, or access to genetic information may 
become too risky for citizens who may fear punitive actions from private entities based 
on the possibility of future disease. 
Synthesis 
 Each of the three manuscripts approached the topic of genetics, genomics, and 
decision-making in a unique way, and, at the same time, the three manuscripts are 
complementary to each other. The behavioral economics and genomics manuscript uses 
an integrative review approach to evaluate the applicability of behavioral economics to 
genomics. As has been previously discussed, the behavioral economic approaches to 
decision-making do not rely solely on the emotions of decision makers (Lerner, Li, 
Valdesolo, & Kassam, 2015). The behavioral economic approaches to describing 
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decision-making behaviors also include some perspective and perception-related concepts 
(Ariely, 2009).  
Some of the behavioral economic concepts are carried over into the second 
manuscript, in order to assist in contextualizing the decision-making processes. The 
analysis utilizes multiple measures to describe different aspects of the context of the 
decisions related to engaging in DTC PGT, and examines them over time. The factor 
analysis of the influencers and motives behind the choice to engage in DTC PGT also 
aids in the contextualization of the decision-making process. The evaluation of 
knowledge, perceptions, beliefs, and the two main factors influencing DTC PGT 
participation across age groups adds another layer of analysis.  These three areas of 
analysis work in conjunction to further describe the contexts in which these decisions are 
made across age groups. 
The third manuscript’s analysis of the DTC PGT results utilization provides 
additional contextualization as the PMT proves to be a valuable tool in better 
understanding reaction-behaviors following results receipt. The four concepts of the PMT 
(perceived vulnerability, perceived severity, response efficacy, and self-efficacy) 
incorporate perspectives of the decision makers and aid in understanding some of the 
driving forces of the decision-making in DTC PGT consumers. The 40-59 and 60+ 
groups were the largest groups that made changes in insurance or finances or advance 
directives in response to their DTC PGT results.   
The three manuscripts follow a logical progression moving from the application 
of the behavioral economic approaches and concepts to genomic decision-making, to the 
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evaluation of contextual factors as they influence DTC PGT engagement, and finally in 
examining the PMT, a model that incorporates some of the contextual factors, as a viable 
tool for studying DTC PGT results utilization. In addition to the progressive focus on 
context and perspective as important factors in genomic testing, these manuscripts also 
seek to examine the age-related differences in engagement in DTC PGT and the 
utilization of the results. Age is an important part of the contexts of decision-making. 
From a behavioral economics perspective, with increasing age the number of experiences 
for a person to draw on in decision-making also increases. Also, older adults may have 
very different perspectives and motives as a result of their advancing age. Their focus 
may be less future-oriented than other age groups.  
 Progressing from behavioral economics to the application of PMT in DTC PGT, 
these three manuscripts address the interface of genetics, genomics, and older adults with 
a specific focus on decision-making. This work further supports the limited existing 
literature that identifies differences in the genetic knowledge of older adults when 
compared to other age groups (Ashida et al. 2011; Carere et al. 2015; Morren et al, 2007). 
The findings in the manuscripts also build on the existing literature and expand that 
knowledge by examining behavioral economics as a lens for examining genomic 
decision-making, the context of engaging in DTC PGT, the age group differences in 
measures of genetic personal utility, self-rated genetic competency, and response 
efficacy, and PMT as a framework for studying genomic decision-making in response to 
DTC PGT results.  
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In addition to the areas where study has been expanded, several findings have the 
potential to shape future study. The findings from the third manuscript support the use of 
the PMT as a model on which to base further study of DTC PGT decision-making.  As of 
the writing of this dissertation, PMT had never been used to study DTC PGT decision-
making nor had it been applied to insurance, retirement, finance, or advance directive 
decision-making as a result of genetic testing. The findings related to age group 
differences may be useful in the design and study of personalized approaches in DTC 
PGT and possibly even clinical genetics. These differences could have implications for 
the study of decision-making, patient education, and results utilization in numerous 
contexts within genetics and healthcare. 
This dissertation addresses a growing area of concern as genetic information is 
becoming a consumer-driven commodity. The field requires further exploration with this 
work beginning to address some key areas of the field of healthcare genetics, specifically 
ethics and policy as well as decision-science. The ethical and policy aspects of the work 
included within this dissertation span genetics and aging.  There is a need for further 
study of the implications of genetic testing and decision-making over a broader and more 
diverse group of tested individuals. This work presents the study and identification of 
some age group differences that may be important in informing policy as the field of 
genetics changes. Decision-making and decision support in DTC PGT and clinical 
genetics are areas that continue to need support in research and practice. The 
understanding of the decision-making processes and contexts is an important part of 
ethical and professional responsibility in the use and application of genetic testing.  
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Decision science is also a key part of the innovation in this dissertation as it 
applies the PMT in new areas: DTC PGT, and making changes to health insurance, 
financial and retirement plans, and advance directives. The dissertation also provides 
further description of the different beliefs, perspectives, and knowledge related to 
genetics and genetic testing which are essential in the study of healthcare genetics. 
Future Directions 
 This dissertation research has created a variety of opportunities for next steps both 
to build on this research and to translate the findings to inform or change practice, 
education, and policy. The findings identified in the three manuscripts of the dissertation 
will be useful in the design and implementation of studies in the clinical genetic testing 
environment. The designs of these studies may vary from the use of a hypothetical 
scenario in evaluating decision-making behavior to the use of a similar type of survey 
evaluating the behavioral economic, PMT, and aging concepts in a clinical genetic testing 
environment. Examination of the concepts in a more diverse population will also be a 
logical next step in expanding this work.   Another area of future work is the translation 
of the findings into designs of novel decision support interventions or decision-making 
aids for clinical practice that allow for generalized support with individualization based 
on the patients’ unique decision-making context. These different areas may be addressed 
individually or may be combined in several ways. 
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APPENDIX A 
DESCRIPTIVE STATISTICS FOR ALL IMPACT OF PERSONAL GENOMICS 
STUDY ITEMS INCLUDED IN DISSERTATION ANALYSES 
Table A.1 
Item-wise Analysis for Genetic Knowledge Scale by Age Group at Baseline and 6 
Month Follow-up 
Item (Correct Answer) Group Baseline  6 Month  
Healthy parents can have a child with 
an inherited disease (T) 
19-39 years old  99.1 (347) 99.7 (349) 
40-59 years old  99.7 (314) 99.0 (312) 
60+ years old  99.1 (221) 98.2 (219) 
Overall   99.3 (882) 99.1 (880) 
If your close relatives have diabetes or 
heart disease, you are more likely to 
develop these conditions (T) 
19-39 years old 96.3 (337) 95.7 (335) 
40-59 years old 96.5 (304) 96.2 (303) 
60+ years old 93.3 (208) 96.0 (214) 
Overall 95.6 (849) 95.9 (852) 
Some genetic disorders occur more 
often within particular ethnic groups 
(T) 
19-39 years old 99.4 (348) 99.4 (348) 
40-59 years old 99.0 (312) 99.4 (313) 
60+ years old 99.6 (222) 99.1 (221) 
Overall 99.3 (882) 99.3 (882) 
Most genetic disorders are caused by 
only a single gene (F) 
 
19-39 years old 65.4 (229) 67.1 (235) 
40-59 years old 61.9 (195) 66.7 (210) 
60+ years old 65.0 (145) 71.3 (159) 
Overall 64.1 (569) 68.0 (604) 
Once a genetic marker for a disorder is 
identified in a person, the disorder can 
usually be prevented or cured (F) 
19-39 years old 87.4 (306) 86.9 (304) 
40-59 years old 87.9 (277) 91.7 (289) 
60+ years old 85.2 (190) 86.1 (192) 
Overall 87.0 (773) 88.4 (785) 
A disease is only genetically 
determined if more than one family 
member is affected (F) 
19-39 years old 90.9 (318) 91.7 (321) 
40-59 years old 89.2 (281) 87.6 (276) 
60+ years old 84.8 (189) 82.5 (184) 
Overall 88.7 (788) 88.0 (781) 
Some of the genetic disorders occur 
later in adult life (T) 
 
19-39 years old 96.0 (336) 98.9 (346) 
40-59 years old 92.1 (290) 94.9 (299) 
60+ years old 91.5 (204) 90.1 (201) 
Overall 93.5 (830) 95.3 (846) 
A healthy lifestyle can prevent or lessen 
the negative consequences of having 
genetic predispositions to some 
diseases (T) 
19-39 years old 97.4 (341) 99.4 (348) 
40-59 years old 97.1 (306) 97.5 (307) 
60+ years old 92.4 (206) 96.9 (216) 
Overall 96.1 (853) 98.1 (871) 
The environment has little or no effect 
on how genes contribute to disease (F) 
19-39 years old 96.0 (336) 97.7 (342) 
40-59 years old 94.6 (298) 93.7 (295) 
60+ years old 90.1 (201) 89.2 (198) 
Overall 94.0 (835) 94.1 (835) 
Note: Values represent % (n). 
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Table A.2 
Item-wise Analysis for Self-Rated Genetic Competency Scale at Baseline Survey 
Item Group SDA DA SWDA N SWA A SA Mean(SD) 
I am confident in my ability to understand information about genetics. 
 19-39 years old 2.0 (7) 0.6 (2) 3.7 (13) 3.7 (13) 12.0 (42) 34.3 (120) 43.7 (153) 6.01 (1.279) 
40-59 years old 1.9 (6) 0.3 (1) 1.0 (3) 3.2 (10) 12.4 (39) 35.6 (112) 45.7 (144) 6.13 (1.143) 
60+ years old 1.3 (3) 0.0 (0) 0.9 (2) 4.5 (10) 15.7 (35) 38.1 (85) 39.5 (88) 6.05 (1.072) 
Overall 1.8 (16) 0.3 (3) 2.0 (18) 3.7 (33) 13.1 (116) 35.7 (317 43.4 (385) 6.06 (1.182) 
I am able to understand information about how genes can affect my health. 
 19-39 years old 1.7 (6) 0.0  (0) 2.3 (8) 3.1 (11) 12.9 (45) 34.3 (120) 45.7 (160) 6.11 (1.156) 
40-59 years old 1.9 (6) 0.0  (0) 1.0 (3) 2.2 (7) 10.8 (34) 38.7 (122) 45.4 (143) 6.18 (1.089) 
60+ years old 0.9 (2) 0.0  (0) 0.4 (1) 0.9 (2) 13.9 (31) 42.6 (95) 41.3 (92) 6.20 (.904) 
Overall 1.6 (14) 0.0  (0) 1.4 (12) 2.3 (20) 12.4 (110) 38.0 (337) 44.5 (395) 6.16 (1.073) 
I have a good idea about how genetics may influence risk for disease generally. 
 19-39 years old 1.4 (5) 1.4 (5) 2.0 (7) 4.3 (15) 18.3 (64) 35.1 (123) 37.4 (131) 5.92 (1.221) 
40-59 years old 2.2 (7) 0.6 (2) 1.9 (6) 4.1 (13) 16.2 (51) 38.7 (122) 36.2 (114) 5.92 (1.231) 
60+ years old 0.9 (2) 1.3 (3) 0.0 (0) 4.5 (10) 18.4 (41) 44.4 (99) 30.5 (68) 5.93 (1.053) 
Overall 1.6 (14) 1.1 (10) 1.5 (13) 4.3 (38) 17.6 (156) 38.7 (344) 35.2 (313) 5.92 (1.184) 
I have a good idea about how my own genetic make-up might affect my risk for disease. 
 19-39 years old 2.3 (8) 2.3 (8) 5.7 (20) 6.6 (23) 20.9 (73) 31.7 (111) 30.6 (107) 5.59 (1.437) 
40-59 years old 1.9 (6) 2.2 (7) 3.2 (10) 9.2 (29) 18.1 (57) 35.2 (111) 30.2 (95) 5.66 (1.363) 
60+ years old 0.9 (2) 2.2 (5) 1.8 (4) 7.6 (17) 18.8 (42) 43.0 (96) 25.6 (57) 5.73 (1.194) 
Overall 1.8 (16) 2.3 (20) 3.8 (34) 7.8 (69) 19.4 (172) 35.8 (318) 29.3 (259) 5.65 (1.353) 
I am able to explain to others how genes affect one’s health. 
 19-39 years old 2.3 (8) 3.1 (11) 6.3 (22) 8.9 (31) 25.4 (89) 28.3 (99) 25.7 (90) 5.40 (1.466) 
40-59 years old 3.5 (11) 1.3 (4) 6.0 (19) 9.8 (31) 28.3 (89) 25.4 (80) 25.7 (81) 5.37 (1.471) 
60+ years old 1.3 (3) 3.1 (7) 5.4 (12) 18.4 (41) 28.7 (64) 25.6 (57) 17.5 (39) 5.17 (1.354) 
Overall 2.5 (22) 2.5 (22) 6.0 (53) 11.6 (103) 27.3 (242) 26.6 (236) 23.6 (210) 5.33 (1.442) 
Note: SDA=Strongly Disagree; DA=Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; A=Agree; 
SA=Strongly Agree.  
Values Represent: %(n) 
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Table A.3 
Item-wise Analysis for Self-Rated Genetic Competency Scale at 6 Month Follow-up Survey 
Item Group SDA DA SWDA N SWA A SA Mean(SD) 
I am confident in my ability to understand information about genetics. 
 19-39 years old 0.9 (3) 2.3 (8) 4.3 (15) 4.9 (17) 20.0 (70) 40.9 (143) 26.9 (94) 5.71 (1.244) 
40-59 years old 1.6 (5) 0.0 (0) 4.1 (13) 4.1 (13) 27.3 (86) 36.8 (116) 26.0 (82) 5.70 (1.176) 
60+ years old 1.3 (3) 3.6 (8) 4.5 (10) 11.2 (25) 24.2 (54) 40.4 (90) 14.8 (33) 5.34 (1.311) 
Overall 1.2 (11) 1.8 (16) 4.3 (38) 6.2 (55) 23.6 (210) 39.3 (349) 23.5 (209) 5.61 (1.247) 
I am able to understand information about how genes can affect my health. 
 19-39 years old 0.9 (3) 1.4 (5) 2.3 (8) 5.1 (18) 24.0 (84) 38.6 (135) 27.7 (97) 5.77 (1.149) 
40-59 years old 1.6 (5) 0.3 (1) 2.5 (8) 3.2 (10) 28.6 (90) 36.2 (114) 27.6 (87) 5.76 (1.145) 
60+ years old 0.9 (2) 0.9 (2) 3.1 (7) 4.9 (11) 26.5 (59) 47.5 (106) 16.1 (36) 5.62 (1.066) 
Overall 1.1 (10) 0.9 (8) 2.6 (23) 4.4 (39) 26.2 (233) 40.0 (355) 24.8 (220) 5.73 (1.128) 
I have a good idea about how genetics may influence risk for disease generally. 
 19-39 years old 0.9 (3) 0.6 (2) 3.1 (11) 4.0 (14) 24.0 (84) 39.7 (139) 27.7 (97) 5.80 (1.108) 
40-59 years old 1.6 (5) 0.6 (2) 1.6 (5) 5.7 (18) 26.3 (83) 39.0 (123) 25.1 (79) 5.72 (1.145) 
60+ years old 0.9 (2) 0.9 (2) 2.2 (5) 5.8 (13) 31.8 (71) 42.6 (95) 15.7 (35) 5.57 (1.050) 
Overall 1.1 (10) 0.7 (6) 2.4 (21) 5.1 (45) 26.8 (238) 40.2 (357) 23.8 (211) 5.71 (1.109) 
I have a good idea about how my own genetic make-up might affect my risk for disease. 
 19-39 years old 0.9 (3) 1.1 (4) 3.4 (12) 3.4 (12) 29.7 (104) 39.1 (137) 22.3 (78) 5.67 (1.120) 
40-59 years old 1.6 (5) 1.0 (3) 1.6 (5) 3.8 (12) 29.8 (94) 39.4 (124) 22.9 (72) 5.69 (1.131) 
60+ years old 0.4 (1) 0.9 (2) 2.7 (6) 5.8 (13) 29.1 (65) 47.5 (106) 13.5 (30) 5.59 (.996) 
Overall 1.0 (9) 1.0 (9) 2.6 (23) 4.2 (37) 29.6 (263) 41.3 (367) 20.3 (180) 5.65 (1.094) 
I am able to explain to others how genes affect one’s health. 
 19-39 years old 1.7 (6) 4.0 (14) 7.4 (26) 9.7 (34) 30.9 (108) 25.7 (90) 20.6 (72) 5.23 (1.435) 
40-59 years old 2.9 (9) 2.5 (8) 9.2 (29) 10.2 (32) 37.1 (117) 22.2 (70) 15.9 (50) 5.06 (1.420) 
60+ years old 4.0 (9) 5.8 (13) 9.4 (21) 18.8 (42) 34.1 (76) 19.3 (43) 8.5 (19) 4.65 (1.468) 
Overall 2.7 (24) 3.9 (35) 8.6 (76) 12.2 (108) 33.9 (301) 22.9 (203) 15.9 (141) 5.03 (1.455) 
Note: SDA=Strongly Disagree; DA=Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; A=Agree; 
SA=Strongly Agree.  
Values Represent: %(n) 
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Table A.4 
Item-wise Analysis for Personal Utility Items at 2-3 Week Follow-up Survey 
Item Group SDA SWDA N SWA SA Mean (SD) 
The information I received from [company] has influenced how I will manage my health in the future. 
 19-39 years old (350) 4.3 (15) 6.6 (23) 15.4 (54) 55.7 (195) 18 .0 (63) 3.77 (.965) 
40-59 years old (315) 4.1 (13) 5.7 (18) 18.1 (57) 50.8 (160) 21.3 (67) 3.79 (.977) 
60+ years old (223) 6.7 (15) 7.2 (16) 24.2 (54) 43.0 (96) 18.8 (42) 3.60 (1.081) 
Overall  (888) 4.8 (43) 6.4 (57) 18.6 (165) 50.8 (451) 19.4 (172) 3.73 (1.001) 
Having personal genomic testing made me feel like I have more control over my health. 
 19-39 years old (350) 2.3 (8) 4.6 (16) 15.7 (55) 47.7 (167) 29.7 (104) 3.98 (.919) 
40-59 years old (315) 4.8 (15) 4.8 (15) 16.8 (53) 46.3 (146) 27.3 (86) 3.87 (1.023) 
60+ years old (223) 8.1 (18) 8.1 (18) 18.8 (42) 38.1 (85) 26.9 (60) 3.68 (1.187) 
Overall  (888) 4.6 (41) 5.5 (49) 16.9 (150) 44.8 (398) 28.2 (250) 3.86 (1.034) 
Having personal genomic testing helped me to get a better perspective on my health status. 
 19-39 years old (350) 1.7 (6) 3.4 (12) 10.3 (36) 49.4 (173) 35.1 (123) 4.13 (0.855) 
40-59 years old (315) 3.2 (10) 2.5 (8) 9.5 (30) 50.2 (158) 34.6 (109) 4.10 (0.906) 
60+ years old (223) 4.5 (10) 4.5 (10) 11.7 (26) 46.2 (103) 33.2 (74) 3.99 (1.151) 
Overall  (888) 2.9 (26) 3.4 (30) 10.4 (92) 48.9 (434) 34.5 (306) 4.09 (1.089) 
Note: SDA=Strongly Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; SA=Strongly Agree.  
Values represent %(n). 
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Table A.5  
Item-wise Analysis for Personal Utility Items at 6 Month Follow-up Survey 
Item Group SDA SWDA N SWA SA Mean (SD) 
The information I received from [company] has influenced how I will manage my health in the future. 
 19-39 years old (350) 6.3 (22) 8.9 (31) 23.7 (83) 45.7 (160) 15.4 (54) 3.55 (1.055) 
40-59 years old (315) 6.3 (20) 7.0 (22) 25.1 (79) 42.2 (133) 19.4 (61) 3.61 (1.72) 
60+ years old (223) 11.2 (25) 7.6 (17) 26.5 (59) 41.7 (93) 13.0 (29) 3.38 (1.151) 
Overall  (888) 7.5 (67) 7.9 (70) 24.9 (221) 43.5 (386) 16.2 (144) 3.53 (1.089) 
Having personal genomic testing made me feel like I have more control over my health. 
 19-39 years old (350) 4.9 (17) 9.4 (33) 18.6 (65) 48.6 (170) 18.6 (65) 3.67 (1.038) 
40-59 years old (315) 6.7 (21) 6.0 (19) 19.o (60 ) 44.8 (141) 23.5 (74) 3.72 (1.093) 
60+ years old (223) 9.9 (22) 6.3 (14) 22.0 (49) 40.8 (91) 21.1 (47) 3.57 (1.179) 
Overall  (888) 6.8 (60) 7.4 (66) 19.6 (174) 45.3 (402) 20.9 (186) 3.66 (1.095) 
Having personal genomic testing helped me to get a better perspective on my health status. 
 19-39 years old (350) 3.1 (11) 6.6 (23) 14.9 (52) 52.0 (182) 23.4 (82) 3.86 (.955) 
40-59 years old (315) 3.8 (12) 4.8 (15) 12.8 (40) 48.9 (154) 29.8 (94) 3.96 (.980) 
60+ years old (223) 7.2 (16) 4.5 (10 ) 16.6 (37) 43.9 (98) 27.8 (62) 3.81 (1.112) 
Overall  (888) 4.4 (39) 5.4 (48) 14.5 (129) 48.9 (434) 26.8 (238) 3.88 (1.006) 
Note: SDA=Strongly Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; SA=Strongly Agree.  
Values represent %(n). 
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Table A.6  
Response Efficacy Item at Baseline and 6 Month Follow-up Surveys 
 Group SDA SWDA N SWA A Mean (SD) 
What I learned from my personal genomic testing can help reduce my chances of getting sick.  
Baseline 
19-39 years old (350) 3.1 (11) 15.3 (54) 20.9 (73) 50.6 (177) 10.0 (35) 3.49 (.975) 
40-59 years old (315) 3.8 (12) 13.0 (41) 29.8 (94) 43.2 (136) 10.2 (32) 3.43 (.970) 
60+ years old (223) 4.5 (10) 9.9 (22) 39.5 (88) 36.8 (82) 9.4 (21) 3.37 (.944) 
Overall  (888) 3.7 (33) 13.2 (117) 28.7 (255) 44.5 (395) 9.9 (88) 3.44 (.965) 
6 Month Follow-up 
19-39 years old (350) 6.9 (24) 16.9 (59) 30.6 (107) 37.4 (131) 8.3 (29) 3.23 (1.047) 
40-59 years old (315) 6.7 (21) 11.7 (37) 29.8 (94) 36.2 (114) 15.6 (49) 3.42 (1.093) 
60+ years old (223) 11.7 (26) 10.3 (23) 32.7 (73) 35.4 (79) 9.9 (22) 3.22 (1.130) 
Overall  (888) 8.0 (71) 13.4 (119) 30.9 (274) 36.5 (324) 11.3 (100) 3.30 (1.088) 
Note: SDA=Strongly Disagree; SWDA= Somewhat Disagree; N=Neutral; SWA=Somewhat Agree; SA=Strongly Agree.  
Values represent %(n). 
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Table A.7 
Item-wise Analysis of Importance of Reasons to Test 
                       Group NI SWI VI Mean (SD) 
Curiosity about my genetic make up 
 
19-39 years old  1.7 (6) 20.6 (72) 77.7 (272) 2.76 (.466) 
40-59 years old  1.6 (5) 21.0 (66) 77.5 (244) 2.76 (.464) 
60+ years old  0.4 (1) 17.0 (38) 82.5 (184) 2.82 (.396) 
Overall   1.4 (12) 19.8 (176) 78.8 (700) 2.77 (.449) 
Interest in finding out about my personal risk for specific diseases 
 
19-39 years old  4.6 (16) 23.1 (81) 72.3 (253) 2.68 (.558) 
40-59 years old  7.0 (22) 29.9 (94) 63.1 (198) 2.56 (.623) 
60+ years old  11.2 (25) 38.6 (86) 50.2 (112) 2.39 (.681) 
Overall   7.1 (63) 29.4 (261) 63.5 (563) 2.56 (.623) 
Desire to learn about my genetic makeup without going through a physician 
 
19-39 years old  34.6 (121) 34.0 (119) 31.4 (110) 1.97 (.813) 
40-59 years old  38.7 (122) 30.2 (95) 32.2 (98) 1.92 (.834) 
60+ years old  51.6 (115) 28.7 (64) 19.7 (44) 1.68 (.784) 
Overall   40.3 (358) 31.3 (278) 28.4 (252) 1.88 (.821) 
Desire to improve my health 
 
19-39 years old  11.4 (4) 41.4 (145) 47.1 (165) 2.36 (.678) 
40-59 years old  10.8 (34) 37.9 (119) 51.3 (161) 2.40 (.677) 
60+ years old  18.8 (42) 38.1 (85) 43.0 (96) 2.24 (.750) 
Overall   13.1 (116) 39.3 (349) 47.6 (422) 2.34 (.699) 
Interest in finding out about my individual response to different types of medications 
 
19-39 years old  18.3 (64) 39.7 (139) 42.0 (147) 2.24 (.740) 
40-59 years old  22.3 (70) 34.7 (109) 43.0 (135) 2.21 (.782) 
60+ years old  24.2 (54) 35.0 (78) 40.8 (91) 2.17 (.791) 
Overall   21.2 (188) 36.8 (326) 42.1 (373) 2.21 (.768) 
Desire to create a better plan for the future 
 
19-39 years old  12.9 (45) 38.3 (134) 48.9 (171) 2.36 (.699) 
40-59 years old  17.8 (56) 34.1 (107) 48.1 (151) 2.30 (.755) 
60+ years old  26.5 (59) 31.4 (70) 42.2 (94) 2.16 (.815) 
Overall   18.0 (160) 35.1 (311) 46.9 (416) 2.29 (.753) 
Personal interest in genetics in general 
 
19-39 years old  6.9 (24) 36.6 (127) 56.9 (199) 2.50 (.623) 
40-59 years old  5.7 (18) 39.4 (124) 54.9 (173) 2.49 (.604) 
60+ years old  8.1 (18) 35.4 (79) 56.5 (126) 2.48 (.643) 
Overall   6.8 (60) 37.2 (330) 56.1 (498) 2.49 (.621) 
The service seemed like it would be fun and entertaining 
 
19-39 years old  16.6 (58) 40.6 (142) 42.9 (150) 2.26 (.726) 
40-59 years old  25.8 (81) 42.7 (134) 31.5 (99) 2.06 (.756) 
60+ years old  25.1 (56) 43.0 (96) 31.8 (71) 2.07 (.753) 
Overall   22.0 (195) 41.9 (372) 36.1 (320) 2.14 (.749) 
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Table A.7 continued 
Item-wise Analysis of Importance of Reasons to Test 
                       Group NI SWI VI Mean (SD) 
Other members of my family are using personal genomic services 
 19-39 years old  80.0 (132) 11.4 (40) 8.6 (30) 1.29 (0.614) 
40-59 years old  82.9 (261) 10.2 (32) 7.0 (22) 1.24 (0.569) 
60+ years old  70.8 (158) 14.8 (33) 14.3 (32) 1.44 (0.732) 
Overall   78.4 (699) 11.8 (105) 9.5 (84) 1.31 (0.634) 
Desire to learn more about my genetics because I have limited information about my 
family health history 
 19-39 years old  30.3 (106) 32.6 (114) 37.1 (130) 2.07 (0.819) 
40-59 years old  32.7 (103) 35.2 (111) 32.1 (101) 1.99 (0.806) 
60+ years old  23.8 (53) 38.6 (86) 37.7 (84) 2.14 (0.773) 
Overall   29.5 (262) 35.0 (311) 35.5 (315) 2.06 (0.804) 
Desire to learn more about my genetics because I am adopted 
 19-39 years old  93.7 (328) 0.6 (2) 5.7 (20) 1.12 (0.470) 
40-59 years old  91.1 (287) 2.5 (8) 6.3 (20) 1.15 (0.507) 
60+ years old  96.4 (215) 0.9 ( 2) 2.7 (6) 1.06 (0.336) 
Overall   93.5 (830) 1.4 (12) 5.2 (46) 1.12 (0.455) 
Interest in getting information about the risk of health conditions for my current 
children or future children. 
 19-39 years old  21.4 (75) 27.4 (96) 51.1 (179) 2.30 (0.800) 
40-59 years old  42.9 (135) 21.0 (66) 36.2 (114) 1.93 (0.888) 
60+ years old  30.5 (68) 26.9 (60) 42.6 (95) 2.21 (0.848) 
Overall   31.3 (278) 25.0 (222) 43.7 (388) 2.12 (0.858) 
Note: NI=Not Important, SWI=Somewhat Important, VI=Very Important. 
Values represent %(n). 
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Table A.8 
Item-wise Analysis of Consideration Given to Reasons to Test 
 Group DNC CSW CAL Mean (SD) 
How well the results predict whether or not I’m going to get a particular disease 
 19-39 years old  15.1 (53) 51.7 (181) 33.1 (116) 2.18 (.672) 
40-59 years old  14.0 (44) 55.2 (174) 30.8 (97) 2.17 (.649) 
60+ years old  24.2 (54) 46.6 (104) 29.1 (65) 2.05 (.730) 
Overall   17.0 (151) 51.7 (459) 31.3 (278) 2.14 (.681) 
Privacy of my genetic information 
 19-39 years old  19.4 (68) 41.7 (146) 38.9 (136) 2.19 (.739) 
40-59 years old  15.9 (50) 38.7 (122) 45.4 (143) 2.30 (.726) 
60+ years old  27.4 (61) 35.0 (78) 37.7 (84) 2.10 (.802) 
Overall   20.2 (179) 39.0 (346) 40.9 (363) 2.21 (.754) 
Whether or not there are health-related actions I can take as a result of learning my 
genetic information 
 19-39 years old  9.1 (32) 38.0 (133) 52.9 (185) 2.44 (.656) 
40-59 years old  7.9 (25) 35.9 (113) 56.2 (177) 2.48 (.640) 
60+ years old  11.7 (26) 39.9 (89) 48.4 (108) 2.37 (.684) 
Overall   9.3 (83) 37.7 (335) 52.9 (470) 2.44 (.658) 
The possibility that I might receive unwanted information  
 19-39 years old  29.1 (102) 41.4 (145) 29.4 (103) 2.00 (.766) 
40-59 years old  33.3 (105) 44.1 (139) 22.5 (71) 1.89 (.741) 
60+ years old  49.8 (111) 37.7 (84) 12.6 (28) 1.63 (.698) 
Overall   35.8 (318) 41.4 (368) 22.7 (202) 1.87 (.754) 
Cost of services 
 19-39 years old  19.4 (68) 41.7 (146) 38.9 (136) 2.19 (.739) 
40-59 years old  21.0 (66) 47.0 (148) 32.1 (101) 2.11 (.721) 
60+ years old  35.9 (80) 45.3 (101) 18.8 (42) 1.83 (.721) 
Overall   24.1 (214) 44.5 (395) 31.4 (279) 2.07 (.742) 
The education materials made available through the company 
 19-39 years old  33.4 (117) 46.0 (161) 20.6 (72) 1.87 (.725) 
40-59 years old  27.0 (85) 50.8 (160) 22.2 (70) 1.95 (.701) 
60+ years old  26.5 (59) 47.1 (105) 26.4 (59) 2.00 (.729) 
Overall   29.4 (261) 48.0 (426) 22.6 (201) 1.93 (.719) 
The convenience of being tested at home 
 19-39 years old  18.9 (66) 37.1 (130) 44.0 (154) 2.25 (.753) 
40-59 years old  16.8 (53) 40.6 (128) 42.5 (134) 2.26 (.727) 
60+ years old  14.3 (32) 35.9 (80) 49.8 (111) 2.35 (.720) 
Overall   17.0 (151) 38.1 (338) 44.9 (399) 2.28 (.736) 
Note: DNC=Did not consider; CSW=Considered Somewhat; CAL=Considered a lot. 
Values Represent % (n). 
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Table A.9 
Perceived Severity Item-wise Analysis Measuring Frequency of Responses to Personal Genomic Testing 
Results 
 Group Never Rarely Sometimes Often Mean (SD) 
Felt upset about my results 
 
19-39 years old  71.7 (251) 21.7 (76) 6.0 (21) 0.6 (2) 1.35 (0.62) 
40-59 years old  73.7 (232) 20.3 (64) 5.7 (18) 0.3 (1) 1.33 (0.60) 
60+ years old  74.0 (165) 17.5 (39) 4.9 (11) 3.6 (8) 1.38 (0.74) 
Overall   73.0 (648) 20.2 (179) 50 (5.6) 1.2 (11) 1.35 (0.64) 
Felt relieved about my resultsa 
 
19-39 years old  15.4 (54) 17.1 (60) 47.4 (166) 20.0 (70) 2.72 (0.96) 
40-59 years old  21.3 (67) 19.7 (62) 44.1 (139) 14.9 (47) 2.53 (0.99) 
60+ years old  19.3 (43) 16.6 (37) 38.6 (86) 25.6 (57) 2.70 (1.05) 
Overall   18.5 (164) 17.9 (159) 44.0 (391) 19.6 (174) 2.65 (1.00) 
Felt happy about my resultsa 
 
19-39 years old  12.3 (43) 19.1 (67) 44.6 (156) 24.0 (84) 2.80 (0.94) 
40-59 years old  15.2 (48) 20.3 (64) 46.7 (147) 17.8 (56) 2.67 (0.94) 
60+ years old  12.1 (27) 14.8 (33) 45.7 (102) 27.4 (61) 2.88 (0.95) 
Overall   13.3 (118) 18.5 (164) 45.6 (405) 22.6 (201) 2.78 (0.95) 
Felt motivated to change my lifestyle because of my results 
 
19-39 years old  29.4 (103) 31.4 (110) 30.0 (105) 9.1 (32) 2.19 (0.96) 
40-59 years old  23.8 (75) 27.6 (87) 34.9 (110) 13.7 (43) 2.38 (0.99) 
60+ years old  26.5 (59) 30.9 (69) 34.1 (76) 8.5 (19) 2.25 (0.94) 
Overall   26.7 (237) 30.0 (266) 32.8 (291) 10.6 (94) 2.27 (0.97) 
Worried about my risk of getting diseases 
 
19-39 years old  36.9 (129) 44.0 (154) 18.0 (63) 1.1 (4) 1.83 (0.75) 
40-59 years old  38.7 (122) 41.9 (132) 15.9 (50) 3.5 (11) 1.84 (0.81) 
60+ years old  44.4 (99) 35.0 (78) 19.7 (44) 0.9 (2) 1.77 (0.79) 
Overall   39.4 (350) 41.0 (364) 17.7 (157) 1.9 (17) 1.82 (0.79) 
Table Continues 
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Table A.9 continued 
Perceived Severity Item-wise Analysis Measuring Frequency of Responses to Personal Genomic Testing 
Results 
 Group Never Rarely Sometimes Often Mean (SD) 
Been uncertain about what my results mean about my risk of developing diseases 
 
19-39 years old  46.3 (162) 32.3 (113) 19.7 (69) 1.7 (6) 1.77 (0.82) 
40-59 years old  47.3 (149) 33.7 (106) 16.2 (51) 2.9 (9) 1.75 (0.83) 
60+ years old  93 (41.7) 35.0 (78) 17.5 (39) 5.8 (13) 1.87 (0.90) 
Overall   45.5 (404) 33.4 (297) 17.9 (159) 3.2 (28) 1.79 (0.85) 
Been uncertain about what my results mean for my child(ren)’s and/or family’s disease risk 
 
19-39 years old  50.3 (176) 28.9 (101) 18.6 (65) 2.3 (8) 1.73 (0.84) 
40-59 years old  55.9 (176) 26.3 (83) 14.6 (46) 3.2 (10) 1.65 (0.84) 
60+ years old  47.1 (105) 27.4 (61) 21.5 (48) 4.0 (9) 1.83 (0.91) 
Overall   51.5 (457) 27.6 (245) 17.9 (159) 3.0 (27) 1.73 (0.86) 
Felt unsure about what to do to prevent diseases 
 
19-39 years old  55.1 (193) 31.1 (109) 11.4 (40) 2.3 (8) 1.61 (0.78) 
40-59 years old  55.6 (175) 28.9 (91) 13.0 (41) 2.5 (8) 1.63 (0.81) 
60+ years old  49.3 (110) 35.0 (78) 13.9 (31) 1.8 (4) 1.68 (0.78) 
Overall   53.8 (478) 31.3 (278) 12.6 (112) 2.3 (20) 1.63 (0.79) 
Felt concerned about how my results will affect my insurance status 
 
19-39 years old  73.4 (257) 15.7 (55) 9.7 (34) 1.1 (4) 1.39 (0.71) 
40-59 years old  64.0 (201) 24.5 (77) 8.9 (28) 2.5 (8) 1.50 (0.76) 
60+ years old  76.7 (171) 14.8 (33) 7.6 (17) 0.9 (2) 1.33 (0.66) 
Overall   70.9 (629) 18.6 (165) 8.9 (79) 1.6 (14) 1.41 (0.72) 
Had difficulty talking about my results with others 
 
19-39 years old  81.7 (286) 14.3 (50) 4.0 (14) 0.0 (0) 1.22 (0.50) 
40-59 years old  72.4 (228) 21.6 (68) 3.8 (12) 2.2 (7) 1.36 (0.66) 
60+ years old  77.1 (172) 14.3 (32) 5.4 (12) 3.1 (7) 1.35 (0.72) 
Overall   77.3 (686) 16.9 (150) 4.3 (38) 1.6 (14) 1.30 (0.63) 
Table Continues 
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Table A.9 continued 
Perceived Severity Item-wise Analysis Measuring Frequency of Responses to Personal Genomic Testing 
Results 
 Group Never Rarely Sometimes Often Mean (SD) 
Wanted to tell others about my resultsa 
 19-39 years old  12.0 (42) 18.6 (65) 46.3 (162) 23.1 (81) 2.81 (0.93) 
40-59 years old  13.0 (41) 19.0 (60) 47.0 (148) 21.0 (66) 2.76 (0.93) 
60+ years old  17.9 (40) 18.4 (41) 46.6 (104) 17.0 (38) 2.63 (0.97) 
Overall   13.9 (123) 18.7 (166) 46.6 (414) 20.8 (185) 2.74 (0.94) 
Note: Values represent % (n) 
aThese results were reverse coded for use in calculation of Perceived Severity Scale 
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Table A.10 
Perceived Vulnerability Item-wise Analysis Measuring Perceptions of Personal Risk for Developing Health Conditions  
 Groups MLTA LTA A HTA MHTA Already Dx Mean (SD) 
Alzheimer’s 
Disease 
19-39 years old  8.9 (31) 34.3 (120) 38.9 (136) 14.3 (50) 3.7 (13) 0.0 (0) 2.70 (0.95) 
40-59 years old  9.2 (29) 34.1 (107) 34.1 (107) 16.9 (53) 5.7 (18) 0.0 (0) 2.76 (1.03) 
60+ years old  17.5 (39) 31.8 (71) 29.6 (66) 17.5 (39) 3.6 (8) 0.0 (0) 2.58 (1.08) 
Overall   11.2 (99) 33.6 (298) 34.8 (309) 16.0 (142) 4.4 (39) 0.0 (0) 2.69 (1.01) 
Breast 
Cancera 
19-39 years old  6.0 (12) 25.1 (50) 51.3 (102) 14.6 (29) 2.5 (5) 0.5 (1) 2.85 (0.95) 
40-59 years old  8.9 (18) 30.7 (62) 46.0 (93) 11.9 (24) 0.5 (1) 2.0 (4) 2.76 (1.21) 
60+ years old  12.8 (16) 27.2 (34) 41.6 (52) 12.8 (16) 2.4 (3) 3.2 (4) 2.84 (1.47) 
Overall   8.7 (46) 27.8 (146) 47.0 (247) 13.1 (69) 1.7 (9) 1.7 (9) 2.82 (1.19) 
Prostate 
Cancera 
19-39 years old  9.3 (14) 17.2 (26) 53.6 (81) 13.2 (20) 6.6 (10) 0.0 (0) 2.91 (0.97) 
40-59 years old  3.6 (4) 22.3 (25) 58.0 (65) 13.4 (15) 0.9 (1) 1.8 (2) 2.96 (1.09) 
60+ years old  7.1 (7) 17.3 (17) 42.9 (42) 15.3 (15) 4.1 (4) 13.3 (13) 3.71 (2.26) 
Overall   6.9 (25) 18.8 (68) 52.1 (188) 13.9 (50) 4.2 (15) 4.2 (15) 3.14 (1.50) 
Colorectal 
Cancer 
19-39 years old  8.3 (29) 19.7 (69) 55.1 (193) 14.6 (51) 2.0 (7) 0.3 (1) 2.84 (0.91) 
40-59 years old  6.7 (21) 21.3 (67) 52.9 (166) 17.5 (55) 1.6 (5) 0.0 (0) 2.86 (0.84) 
60+ years old  7.2 (16) 34.1 (76) 40.8 (91) 14.3 (32) 3.6 (8) 0.0 (0) 2.73 (0.92) 
Overall   7.4 (66) 23.9 (212) 50.7 (450) 15.6 (138) 2.3 (20) 0.1 (1) 2.82 (0.89) 
Lung Cancer 19-39 years old  13.1 (46) 24.6 (86) 49.1 (172) 10.9 (38) 2.3 (8) 0.0 (0) 2.65 (0.92) 
40-59 years old  15.0 (47) 28.7 (90) 44.6 (140) 10.5 (33) 1.0 (3) 0.3 (1) 2.56 (0.98) 
60+ years old  24.7 (55) 30.5 (68) 30.0 (67) 13.0 (29) 0.9 (2) 0.9 (2) 2.40 (1.20) 
Overall   16.7 (148) 27.5 (244) 42.7 (379) 11.3 (100) 1.5 (13) 0.3 (3) 2.55 (1.02) 
Diabetes 19-39 years old  9.7 (34) 20.6 (72 ) 45.1 (158) 18.6 (65) 5.1 (18) 0.9 (3) 2.94 (1.14) 
40-59 years old  8.6 (27) 24.5 (77) 38.2 (120) 22.3 (70) 4.5 (14) 1.9 (6) 3.01 (1.30) 
60+ years old  13.5 (30) 25.1 (56) 34.4 (77) 14.8 (33) 4.5 (10) 7.6 (17) 3.17 (1.96) 
Overall   10.3 (91) 23.1 (205) 40.0 (355) 18.9 (168) 4.7 (42) 2.9 (26) 3.02 (1.44) 
Table Continues 
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Table A.10 continued 
Perceived Vulnerability Item-wise Analysis Measuring Perceptions of Personal Risk for Developing Health Conditions 
Groups MLTA LTA A HTA MHTA Already Dx Mean (SD) 
Heart 
Disease 
19-39 years old  7.4 (26) 18.6 (65) 40.6 (142) 26.6 (93) 6.6 (23) 0.3 (1) 3.08 (1.05) 
40-59 years old  3.8 (12) 14.6 (46) 42.4 (133) 33.1 (104) 5.7 (18) 0.3 (1) 3.24 (0.96) 
60+ years old  5.4 (12) 22.4 (50) 35.4 (79) 24.2 (54) 5.4 (12) 7.2 (16) 3.45 (1.82) 
Overall   5.6 (50) 18.2 (161) 39.9 (354) 28.3 (251) 6.0 (53) 2.0 (18) 3.23 (1.27) 
Obesity 19-39 years old  15.7 (55) 21.4 (75) 38.9 (136) 16.3 (57) 2.6 (9) 5.1 (18) 2.99 (1.72) 
40-59 years old  10.5 (33) 14.6 (46) 36.9 (116) 22.6 (71) 3.2 (10) 12.1 (38) 3.66 (2.20) 
60+ years old  17.0 (38) 17.9 (40) 30.5 (68) 21.5 (48) 3.6 (8) 9.4 (21) 3.33 (2.13) 
Overall   14.2 (126) 18.2 (161) 36.1 (320) 19.8 (176) 3.0 (27) 8.7 (77) 3.31 (2.03) 
Parkinson’s 
Disease 
19-39 years old  11.7 (41) 27.1 (95) 51.1 (179) 9.7 (34) 0.3 (1) 0.0 (0) 2.60 (0.83) 
40-59 years old  10.8 (34) 32.2 (101) 46.2 (145) 7.3 (23) 2.5 (8) 1.0 (3) 2.64 (1.07) 
60+ years old  16.6 (37) 39.0 (87) 32.7 (73) 7.2 (16) 1.8 (4) 2.7 (6) 2.55 (1.40) 
Overall   12.6 (112) 31.9 (283) 44.8 (397) 8.2 (73) 1.5 (13) 1.0 (9) 2.60 (1.08) 
Note: MLTA=Much Lower Than Average; LTA= Lower Than Average; A=Average; HTA= Higher Than Average; 
MHTA=Much Higher Than Average. Values represent % (n). 
aThis item asked based on participant’s reported sex. 
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Table A.11 
Complete Demographics of the Participant Sample Used for Dissertation Analyses 
Gender Group Male Female 
19-39 years old 43.1 (151) 56.9 (199) 
40-59 years old 35.9 (113) 64.1 (202) 
60+ years old 42.9 (98) 56.1 (125) 
Overall 40.8 (362) 59.2 (526) 
Adopted Group Yes No 
19-39 years old 6.0 (21) 94 (329) 
40-59 years old 7.9 (25) 92.1 (290) 
60+ years old 2.2 (5) 97.8 (218) 
Overall 5.7 (51) 94.3 (837) 
Relationship 
Status 
Group Single Married Widowed Divorced/Sep Partnered/LTR 
19-39 years old 36.3 (127) 34.6 (121) 0.0 (0) 5.1 (18) 24.0 (84) 
40-59 years old 14.6 (46) 61.0 (192) 1.6 (5) 12.4 (39) 10.5 (33) 
60+ years old 5.4 (12) 66.8 (149) 6.3 (14) 12.6 (28) 9.0 (20) 
Overall 20.8 (185) 52.0 (462) 2.1 (19) 9.6 (85) 15.4 (137) 
Biological 
Children 
Group Yes No 
19-39 years old 18.9 (66) 81.1 (284) 
40-59 years old 60.6 (191) 39.4 (124) 
60+ years old 78.5 (175) 21.5 (48) 
Overall 48.6 (432) 51.4 (456) 
Number of 
Biological 
Children 
Group 1 2 3 4 5 6 7+ 
19-39 years old 51.5 (34) 42.4 (28) 4.5 (3) 1.5 (1) 0.0 (0) 0.0 (0) 0.0 (0) 
40-59 years old 25.7 (49) 45.5 (87) 21.5 (41) 5.2 (10) 2.1 (4) 0.0 (0) 0.0 (0) 
60+ years old 17.7 (31) 48.6 (85) 25.7 (45) 2.3 (4) 4.0 (7) 1.1 (2) 0.6 (1) 
Overall 26.4 (114) 46.3 (200) 20.6 (89) 3.5 (15) 2.5 (11) 0.5 (2) 0.2 (1) 
Table Continues 
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Table A.11 continued 
Complete Demographics of the Participant Sample Used for Dissertation Analyses 
Are any 
Biological 
Children 
under 18? 
Group Yes No 
19-39 years old 95.5 (63) 4.5 (3) 
40-59 years old 44.0 (84) 56.0 (107) 
60+ years old 0.6 (1) 99.4 (174) 
Overall 34.3 (148) 65.7 (284) 
Hispanic/ 
Latino 
Group Yes No 
19-39 years old 6.9 (24) 93.1 (3.26) 
40-59 years old 5.1 (16) 94.9 (299) 
60+ years old 1.3 (3) 98.7 (220) 
Overall 4.8 (43) 95.2 (845) 
Race 
Group 
Am Indian 
/Native 
Alaskan 
Asian 
Black or 
African 
American 
Hawaiian or 
Pacific 
Islander 
White Other 
19-39 years old 3.1 (11) 9.7 (34) 3.7 (13) 1.4 (5) 86.6 (303) 7.4 (26) 
40-59 years old 1.9 (6) 2.2 (7) 3.8 (12) 0.3 (1) 92.4 (291) 4.8 (15) 
60+ years old 3.6 (8) 0.0 (0) 1.3 (3) 0.4 (1) 95.5 (213) 3.1 (7) 
Overall 2.8 (25) 4.6 (41) 3.2 (28) 0.8 (7) 90.9 (807) 5.4 (48) 
Household 
Income 
Past 12 
months 
Group <$40,000 
$40,000-
$69,999 
$70,000-
$99,999 
$100,000-
$199,000 
$200,000-
$500,000 
>$500,000 
19-39 years old 24.6 (93) 16.3 (57) 18.0 (63) 29.1 (102) 8.3 (29) 1.7 (6) 
40-59 years old 11.8 (36) 16.0 (49) 20.6 (63) 36.3 (111) 12.4 (38) 2.9 (9) 
60+ years old 12.7 (28) 23.1 (51) 22.6 (50) 28.1 (62) 12.2 (27) 1.4 (3) 
Overall 17.9 (157) 17.9 (157) 20.1 (176) 31.4 (275) 10.7 (94) 2.1 (18) 
Table Continues 
  
  
1
1
2 
Table A.11 continued 
Complete Demographics of the Participant Sample Used for Dissertation Analyses 
Highest 
Level  
of Ed. 
Group 
Grade 
Sch. 
HS/ 
GED 
Some 
College 
College 
Degree 
Some 
Grad 
Sch. 
Master’s 
Degree 
Some 
Doc. 
Work 
PhD, 
DSc, 
EdD 
Doc. Equiv. 
19-39 
years 
old 
0.3 (1) 2.9 (10) 14.0 (49) 37.1 (130) 12.0 (42) 18.0 (63) 5.1 (18) 6.0 (21) 4.5 (16) 
40-59 
years 
old 
0.0 (0) 2.9 (9) 17.8 (56) 31.1 (98) 11.7 (37) 20.3 (64) 2.2 (7) 6.7 (21) 7.3 (23) 
60+ 
years 
old 
0.9 (2) 4.0 (9) 20.2 (45) 17.9 (40) 11.7 (26) 24.7 (55) 3.6 (8) 8.5 (19) 8.5 (19) 
Overall 0.3 (3) 3.2 (28) 16.9 (150) 30.2 (268) 11.8 (105) 20.5 (182) 3.7 (33) 6.9 (61) 6.6 (58) 
Current 
Employ
ment 
Status 
Group 
Full Time Part-time Retired 
Self-
employed 
Unemployed Student 
Not 
working 
by choice 
19-39 
years 
old 
62.9 (220) 12.6 (44) 0.6 (2) 5.7 (20) 8.0 (28) 20.3 (71) 4.6 (16) 
40-59 
years 
old 
58.7 (185) 6.7 (21) 11.1 (35) 13.0 (41) 7.3 (23) 1.6 (5) 9.2 (29) 
60+ 
years 
old 
22.4 (50) 9.0 (20) 63.2 (141) 7.6 (17) 2.7 (6) 0.0 (0) 3.6 (8) 
Overall 51.2 (455) 9.6 (85) 20.0 (178) 8.8 (78) 6.4 (57) 8.6 (76) 6.0 (53) 
Note: Values represent % (n). 
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